Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

ABSTRACT

Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.

This application is a continuation of U.S. application Ser. No.16/624,301, filed Dec. 19, 2019 which is a U.S. National Stage filingunder 35 U.S.C. § 371 of International Application No.PCT/US2018/038697, filed Jun. 21, 2018, which claims the benefit of andpriority to U.S. Provisional Application No. 62/523,688, filed Jun. 22,2017, the entire contents of each of which are incorporated herein byreference.

1. FIELD

Provided herein are methods for treating and/or preventinghepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV)infection in a patient, comprising administering an effective amount of7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-oneor a pharmaceutically acceptable salt or tautomer thereof (collectivelyreferred to herein as “Compound 1”) to the patient having HCCcharacterized by HBV infection. Further provided herein are compoundsfor use in such methods. Particularly provided herein is7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-oneor a pharmaceutically acceptable salt or tautomer thereof for use insuch methods.

2. BACKGROUND

The connection between abnormal protein phosphorylation and the cause orconsequence of diseases has been known for over 20 years. Accordingly,protein kinases have become a very important group of drug targets. SeeCohen, Nat. Rev. Drug Disc., 2002, 1:309-315, Grimmiger et al., Nat.Rev. Drug Disc., 2010, 9(12):956-970. Various protein kinase inhibitorshave been used clinically in the treatment of a wide variety ofdiseases, such as cancer and chronic inflammatory diseases, includingdiabetes and stroke. See Cohen, Eur. J. Biochem., 2001, 268:5001-5010,Protein Kinase Inhibitors for the Treatment of Disease: The Promise andthe Problems, Handbook of Experimental Pharmacology, Springer BerlinHeidelberg, 2005, 167.

The protein kinases belong to a large and diverse family of enzymes thatcatalyze protein phosphorylation and play a critical role in cellularsignaling. Protein kinases may exert positive or negative regulatoryeffects, depending upon their target protein. Protein kinases areinvolved in specific signaling pathways which regulate cell functionssuch as, but not limited to, metabolism, cell cycle progression, celladhesion, vascular function, apoptosis, and angiogenesis. Malfunctionsof cellular signaling have been associated with many diseases, the mostcharacterized of which include cancer and diabetes. The regulation ofsignal transduction by cytokines and the association of signal moleculeswith protooncogenes and tumor suppressor genes have been welldocumented. Similarly, the connection between diabetes and relatedconditions, and deregulated levels of protein kinases, has beendemonstrated. See e.g., Sridhar et al., Pharm. Res., 2000,17(11):1345-1353. Viral infections and the conditions related theretohave also been associated with the regulation of protein kinases. Parket al., Cell, 2000, 101(7):777-787.

The protein named mTOR (mammalian target of rapamycin), also calledFRAP, RAFTI or RAPT1), is a 2549-amino acid Ser/Thr protein kinase, thathas been shown to be one of the most critical proteins in themTOR/PI3K/Akt pathway that regulates cell growth and proliferation.Georgakis and Younes, Expert Rev. Anticancer Ther., 2006, 6(1):131-140.mTOR exists within two complexes, mTORC1 and mTORC2. While mTORC1 issensitive to rapamycin analogs (such as temsirolimus or everolimus),mTORC2 is largely rapamycin-insensitive. Notably, rapamycin is not a TORkinase inhibitor. Several mTOR inhibitors have been or are beingevaluated in clinical trials for the treatment of cancer. Temsirolimuswas approved for use in renal cell carcinoma in 2007 and everolimus wasapproved in 2009 for renal cell carcinoma patients that have progressedon vascular endothelial growth factor receptor inhibitors. In addition,sirolimus was approved in 1999 for the prophylaxis of renal transplantrejection. The interesting but limited clinical success of these mTORC1inhibitory compounds demonstrates the usefulness of mTOR inhibitors inthe treatment of cancer and transplant rejection, and the increasedpotential for compounds with both mTORC1 and mTORC2 inhibitory activity.

HCC, also known as malignant hepatoma, is the most common primarymalignancy of the liver and accounts for 80-90% of primary liver tumors.HCC is one of the most common and devastating malignant diseasesworldwide, responsible for more than 1 million deaths annually in theworld (Parkin et al., CA Cancer J. Clin. 1999, 49:33-64; Bruix et al.,Cancer Cell, 2004, 5:215-219).

The major risk factors for the development of HCC include hepatitis B orC viral infection, and alcoholic liver disease (Rustgi, Gastroenterol.Clin. North Am., 1987, 16:545-551; Bosch et al., Semin. Liver Dis.,1999, 19:271-285; Bosch et al., Gastroenterology, 2004, 127:S5-S16;Moradpour et al., Eur. J. Gastro & Hepatol., 2005, 17:477-483; Koike etal., J. Gastroenterol. Hepatol., 2008, 23:S87-S91; de Oliveria Andrade,J. Glob. Infect. Dis., 2009, 1:33-37). HCC arises most commonly incirrhotic livers following infection with HBV or hepatitis C virus (HCV)(Liaw, Semin. Liver Dis., 2005, 25:40-47; Koike, Clin. Gastroenterol.Hepatol., 2005, 3:132-135). HCC is associated with HBV infection inabout 50% of cases (Liaw, Semin. Liver Dis., 2005, 25:40-47). HCVinfection is the cause of 70% of the cases of HCC in Japan (Hasan etal., Hepatology, 1990, 12:589-591; El-Serag et al., N. Engl. J. Med.,1999, 340:745-750). The HCC incidence has been increasing in Westerncountries in recent years due to the spread of HCV infection (El-Serag,Hepatology, 2002, 36:S74-83; Trevisani et al., Carcinogenesis, 2008,29:1299-1305) and increasing incidence of non-alcoholic steatosis(Torres et al., Semin. Liver. Dis., 2012, 32(1):30-38).

HCC has poor prognosis with median survival less than 2 years from thedate of prognosis. HCC survival rates vary across studies but generallyare 10-20% for 5 year survival. HBV-related HCC has extremely poorprognosis with median survival less than 16 months. Survival rates ofHBV-related HCC ranged from 36% to 67% after 1 year and from 15% to 26%after 5 year of diagnosis. (Nguyen et al., J. Viral. Hepat., 2009,16(7):453-463).

Although various chemotherapy regimens are available, traditionally,chemotherapy is not considered an effective treatment option for HCC.Systemic chemotherapy response rates of 10% can be seen, with responserates up to 20% using intra-arterial chemotherapy. Treatment options forsubjects with unresectable HCC are severely limited and there remains ahigh unmet medical need for effective therapies in this disease.

Citation or identification of any reference in Section 2 of thisapplication is not to be construed as an admission that the reference isprior art to the present application.

3. SUMMARY

In one aspect, provided herein is a method for treating and/orpreventing HCC characterized by HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such a method for treating and/or preventing HCC characterized byHBV infection in a patient. In certain embodiments, provided herein is amethod for treating HCC characterized by HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for treating HCC characterized byHBV infection in a patient. In other embodiments, provided herein is amethod for preventing HCC characterized by HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for preventing HCC characterized byHBV infection in a patient.

In certain embodiments, the HCC characterized by HBV infection isunresectable HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating unresectable HCCcharacterized by HBV infection in a patient, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such a methodfor treating unresectable HCC characterized by HBV infection in apatient. In other embodiments, provided herein is a method forpreventing unresectable HCC characterized by HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for preventing unresectable HCCcharacterized by HBV infection in a patient.

In another aspect, provided herein is a method for treating and/orpreventing HCC characterized by HBV infection in a patient, comprisingscreening a biological test sample from the patient for HBV infection,and administering an effective amount of Compound 1 to the patienthaving HCC characterized by HBV infection. Provided herein is Compound 1for use in such a method for treating and/or preventing HCCcharacterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. In certainembodiments, provided herein is a method for treating HCC characterizedby HBV infection in a patient, comprising screening a biological testsample from the patient for HBV infection, and administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such a methodfor treating HCC characterized by HBV infection in a patient, whereinthe method comprises screening a biological test sample from the patientfor HBV infection, and administering an effective amount of Compound 1to the patient having HCC characterized by HBV infection. In otherembodiments, provided herein is a method for preventing HCCcharacterized by HBV infection in a patient, comprising screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such a method for preventing HCC characterized by HBV infectionin a patient, wherein the method comprises screening a biological testsample from the patient for HBV infection, and administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection.

In certain embodiments, the HCC characterized by HBV infection isunresectable HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating unresectable HCCcharacterized by HBV infection in a patient, comprising screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for treating unresectable HCCcharacterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having unresectable HCC characterized by HBV infection. In yetother embodiments, provided herein is a method for preventingunresectable HCC characterized by HBV infection in a patient, comprisingscreening a biological test sample from the patient for HBV infection,and administering an effective amount of Compound 1 to the patienthaving HCC characterized by HBV infection. Provided herein is Compound 1for use in such a method for preventing unresectable HCC characterizedby HBV infection in a patient, wherein the method comprises screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection.

In yet another aspect, provided herein is a method for selecting apatient having HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having HCC for Compound 1 treatmentif HBV infection is determined in the sample. In certain embodiments,the method further comprises a step d) administering an effective amountof Compound 1 to the patient having HCC characterized by HBV infection.Thus, in some embodiments, provided herein is a method for selecting apatient having HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having HCC for Compound 1 treatmentif HBV infection is determined in the sample; and d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, also provided herein is Compound 1 for use in amethod for selecting a patient having HCC for Compound 1 treatment,wherein the method comprises a) obtaining a biological test sample fromthe patient; b) analyzing the sample for HBV infection; c) selecting thepatient having HCC for Compound 1 treatment if HBV infection isdetermined in the sample; and d) administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection.

In certain embodiments, the HCC is unresectable HCC. Thus, in someembodiments, provided herein is a method for selecting a patient havingunresectable HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having unresectable HCC for Compound1 treatment if HBV infection is determined in the sample. In otherembodiments, provided herein is a method for selecting a patient havingunresectable HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having unresectable HCC for Compound1 treatment if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Thus, also providedherein is Compound 1 for use in a method for selecting a patient havingunresectable HCC for Compound 1 treatment, wherein the method comprisesa) obtaining a biological test sample from the patient; b) analyzing thesample for HBV infection; c) selecting the patient having unresectableHCC for Compound 1 treatment if HBV infection is determined in thesample; and d) administering an effective amount of Compound 1 to thepatient having unresectable HCC characterized by HBV infection.

In still another aspect, provided herein is a method for predictingresponse to treatment with Compound 1 in a patient having HCC, themethod comprising: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's HCC if HBV infection is determined in the sample. In certainembodiments, the method further comprises a step d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, in some embodiments, provided herein is a methodfor predicting response to treatment with Compound 1 in a patient havingHCC, the method comprising: a) obtaining a biological test sample fromthe patient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's HCC if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Thus, also provided herein isCompound 1 for use in a method for predicting response to treatment withCompound 1 in a patient having HCC, wherein the method comprises: a)obtaining a biological test sample from the patient; b) analyzing thesample for HBV infection; c) predicting an increased likelihood ofresponse to the Compound 1 treatment of the patient's HCC if HBVinfection is determined in the sample; and d) administering an effectiveamount of Compound 1 to the patient having HCC characterized by HBVinfection.

In certain embodiments, the HCC is unresectable HCC. Thus, in someembodiments, provided herein is a method for predicting response totreatment with Compound 1 in a patient having unresectable HCC, themethod comprising: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's unresectable HCC if HBV infection is determined in the sample.In other embodiments, provided herein is a method for predictingresponse to treatment with Compound 1 in a patient having unresectableHCC, the method comprising: a) obtaining a biological test sample fromthe patient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's unresectable HCC if HBV infection is determined in the sample;and d) administering an effective amount of Compound 1 to the patienthaving unresectable HCC characterized by HBV infection. Thus, alsoprovided herein is Compound 1 for use in a method for predictingresponse to treatment with Compound 1 in a patient having unresectableHCC, wherein the method comprises: a) obtaining a biological test samplefrom the patient; b) analyzing the sample for HBV infection; c)predicting an increased likelihood of response to the Compound 1treatment of the patient's unresectable HCC if HBV infection isdetermined in the sample; and d) administering an effective amount ofCompound 1 to the patient having unresectable HCC characterized by HBVinfection.

In another aspect, provided herein is a method for predictingtherapeutic efficacy of Compound 1 in a patient having HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient's HCC ifHBV infection is determined in the sample. In certain embodiments, themethod further comprises a step d) administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection.Thus, in some embodiments, provided herein is a method for predictingtherapeutic efficacy of Compound 1 in a patient having HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient's HCC ifHBV infection is determined in the sample; and d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, also provided herein is Compound 1 for use in amethod for predicting therapeutic efficacy of Compound 1 in a patienthaving HCC, wherein the method comprises: a) obtaining a biological testsample from the patient; b) analyzing the sample for HBV infection; c)predicting an increased likelihood of therapeutic efficacy of Compound 1in the patient's HCC if HBV infection is determined in the sample; andd) administering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection.

In certain embodiments, the HCC is unresectable HCC. Thus, in someembodiments, provided herein is a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient'sunresectable HCC if HBV infection is determined in the sample. In otherembodiments, provided herein is a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient'sunresectable HCC if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Thus, also providedherein is Compound 1 for use in a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, wherein themethod comprises: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of therapeutic efficacy of Compound 1 in thepatient's unresectable HCC if HBV infection is determined in the sample;and d) administering an effective amount of Compound 1 to the patienthaving unresectable HCC characterized by HBV infection.

The present embodiments can be understood more fully by reference to thedetailed description and examples, which are intended to exemplifynon-limiting embodiments.

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts study design for Part B of the clinical study of Example6.1.

FIG. 2. shows patient characteristics for the Part B HCC cohort.

FIGS. 3A and 3B show pharmacokinetics (PK) data of Compound 1 (FIG. 3A)and its metabolite M1 (FIG. 3B) in HCC-HBV positive patients (n=12) andHCC-HBV negative patients (n=39).

FIG. 4 shows disposition of HCC treated population (TP) by HBV status.

FIGS. 5A and 5B show Kaplan-Meier curve for overall survival (OS) forHCC cohort. FIG. 5A shows OS for all HCC patients withoutdifferentiating HBV infected and non-HBV infected patients. FIG. 5Bshows OS by HBV status for HCC cohort (p=0.19).

FIGS. 6A and 6B show Kaplan-Meier curve for progression free survival(PFS) for HCC cohort. FIG. 6A shows PFS for all HCC patients withoutdifferentiating HBV infected and non-HBV infected patients. FIG. 6Bshows PFS by HBV status for HCC cohort.

FIG. 7 shows best percentage change from baseline in total length oftarget lesions in efficacy-evaluable HBV infected versus non-HBVinfected patients receiving Compound 1.

FIG. 8 summarizes survival and response data for HBV infected versusnon-HBV infected patients receiving Compound 1.

FIG. 9 shows an exemplary radiographic response from two HBV infectedHCC patients treated with Compound 1. Patient A shows regression ofintrathoracic metastases at the first on-treatment restaging compared tobaseline. Patient B shows intrahepatic tumor regression at the firston-treatment restaging compared to baseline.

FIG. 10 shows exemplary alpha-fetoprotein (AFP) response in two HCCpatients with partial response (PR) receiving Compound 1 treatment. Bothpatients show early clinically significant, marked reduction of AFP ontreatment compared to baseline elevated levels.

5. DETAILED DESCRIPTION 5.1 Definitions

The use of the word “a” or “an” when used in conjunction with the term“comprising” in the claims and/or the specification can mean “one”, butit is also consistent with the meaning of “one or more”, “at least one”and “one or more than one.”

As used herein, the terms “comprising” and “including” can be usedinterchangeably. The terms “comprising” and “including” are to beinterpreted as specifying the presence of the stated features orcomponents as referred to, but does not preclude the presence oraddition of one or more features, or components, or groups thereof.Additionally, the terms “comprising” and “including” are intended toinclude examples encompassed by the term “consisting of”. Consequently,the term “consisting of” can be used in place of the terms “comprising”and “including” to provide for more specific embodiments of theinvention.

The term “consisting of” means that a subject-matter has at least 90%,95%, 97%, 98% or 99% of the stated features or components of which itconsists. In another embodiment the term “consisting of” excludes fromthe scope of any succeeding recitation any other features or components,excepting those that are not essential to the technical effect to beachieved.

As used herein, the term “or” is to be interpreted as an inclusive “or”meaning any one or any combination. Therefore, “A, B or C” means any ofthe following: “A; B; C; A and B; A and C; B and C; A, B and C”. Anexception to this definition will occur only when a combination ofelements, functions, steps or acts are in some way inherently mutuallyexclusive.

As used herein, the term “pharmaceutically acceptable salt(s)” refers toa salt prepared from a pharmaceutically acceptable non-toxic acid orbase including an inorganic acid and base and an organic acid and base.Suitable pharmaceutically acceptable base addition salts of Compound 1include, but are not limited to, metallic salts made from aluminum,calcium, lithium, magnesium, potassium, sodium and zinc or organic saltsmade from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline,diethanolamine, ethylenediamine, meglumine (N-methylglucamine) andprocaine. Suitable non-toxic acids include, but are not limited to,inorganic and organic acids such as acetic, alginic, anthranilic,benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic,formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic,glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic,mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic,phenylacetic, phosphoric, propionic, salicylic, stearic, succinic,sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid.Specific non-toxic acids include hydrochloric, hydrobromic, phosphoric,sulfuric, and methanesulfonic acids. Examples of specific salts thusinclude hydrochloride and mesylate salts. Others are well-known in theart, see for example, Remington's Pharmaceutical Sciences, 18^(th) eds.,Mack Publishing, Easton Pa. (1990) or Remington: The Science andPractice of Pharmacy, 19^(th) eds., Mack Publishing, Easton Pa. (1995).

“Tautomer” refers to isomeric forms of a compound that are inequilibrium with each other. The concentrations of the isomeric formswill depend on the environment the compound is found in and may bedifferent depending upon, for example, whether the compound is a solidor is in an organic or aqueous solution. For example, in aqueoussolution, pyrazoles may exhibit the following isomeric forms, which arereferred to as tautomers of each other:

As readily understood by one skilled in the art, a wide variety offunctional groups and other structures may exhibit tautomerism and alltautomers of Compound 1 are within the scope of the present invention.

“Treating” as used herein, means an alleviation, in whole or in part, ofsymptoms associated with a disorder or disease (e.g., HCC characterizedby HBV infection), or slowing, or halting of further progression orworsening of those symptoms.

“Preventing” as used herein, means the prevention of the onset,recurrence or spread, in whole or in part, of the disease or disorder(e.g., HCC characterized by HBV infection), or a symptom thereof.

As used herein, “administer” or “administration” refers to the act ofphysically delivering a substance as it exists outside the body into apatient, such as by oral, mucosal, intradermal, intravenous,intramuscular delivery and/or any other method of physical deliverydescribed herein or known in the art. When a disease, disorder orcondition, or a symptom thereof, is being treated, administration of thesubstance typically occurs after the onset, recurrence or spread ofdisease, disorder or condition or symptoms thereof. When a disease,disorder or condition, or symptoms thereof, are being prevented,administration of the substance typically occurs before the onset,recurrence or spread of the disease, disorder or condition or symptomsthereof.

The term “effective amount” in connection with Compound 1 means anamount alone or in combination capable of alleviating, in whole or inpart, a symptom associated with HCC, or slowing or halting furtherprogression or worsening of those symptoms, or treating or preventingHCC in a subject having or at risk for having HCC. The effective amountof Compound 1, for example in a pharmaceutical composition, may be at alevel that will exercise the desired effect; for example, about 0.005mg/kg of a subject's body weight to about 10 mg/kg of a patient's bodyweight in unit dosage for both oral and parenteral administration.

As used herein, the term “combination” or administration “incombination” includes administration as a mixture, simultaneousadministration using separate formulations, and consecutiveadministration in any order.

“Consecutive” means that a specific time has passed between theadministration of the active agents. For example, “consecutive” may bethat more than 10 minutes have passed between the administration of theseparate active agents. The time period can then be more than 10 min,more than 30 minutes, more than 1 hour, more than 3 hours, more than 6hours or more than 12 hours.

As used herein, the term “immune checkpoint inhibitor” or “checkpointinhibitor” refers to molecules that totally or partially reduce,inhibit, interfere with or modulate one or more checkpoint proteins.Without being limited by a particular theory, checkpoint proteinsregulate T-cell activation or function. Non-limiting examples ofcheckpoint inhibitors include CTLA-4, CD80, CD86, PD-1, PD-L1, and PD-L2(Pardoll, Nature Rev. Cancer, 2012, 12:252-264).

The terms “patient” and “subject” as used herein include an animal,including, but not limited to, an animal such as a cow, monkey, horse,sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit orguinea pig, in one embodiment a mammal, in another embodiment a human.

As used herein, the term “treated population” or “TP” refers to allenrolled subjects who took at least 1 dose of Compound 1. Drug exposureand all safety analyses are based on the treated population.

As used herein, the term “efficacy evaluable population” or “EEpopulation” refers to all subjects who met eligibility criteria,completed at least 1 cycle of Compound 1 treatment, and had baseline andat least 1 postbaseline efficacy assessment. Efficacy assessment meansradiological or clinical assessment of given type of tumor, or tumorassessment by other appropriate means described by relevant tumorresponse criteria. Specifically, efficacy assessment may include validradiologic tumor assessment for subjects with HCC. In addition, subjectsare to take at least 70% of assigned days of Compound 1 during Cycle 1or have Cycle 2 dosing records to be defined as having completed atleast 1 treatment cycle.

As used herein, the term “biological test sample” refers to a sampletaken from serum, plasma, blood, dried blood/plasma spots, hepatocytes,primary tumor, or sites of metastasis of HCC, including but not limitedto, lungs, lymph nodes, adrenal glands, bones, peritoneum, portal vein,brain, saliva, parotid tissue, etc.

The term “HBV positive” or “HBV infected,” used interchangeably herein,refers to the HBV status of HCC patients, which is determined by analgorithm to identify subjects with HCC considered to have been infectedwith HBV. Variables useable for the algorithm include but are notlimited to the following: medical history of HBV, immunization history,prior or current treatment for HBV, cirrhosis attributed to HBV,serological testing for HBV antigens and/or antibodies, HBV load, andthe presence of HBV DNA. Non-limiting examples of such variables are thepresence of HBV surface antigen (HBsAg), the presence of antibody to HBVsurface antigen (anti-HBsAg), the presence of HBV core antigen (HBcAg),the presence of antibody to HBV core antigen (anti-HBcAg), the presenceof HBV envelope protein antigen (HBeAg), the presence of antibody to HBVenvelope protein antigen (anti-HBeAg), the presence of HBV x-proteinantigen (HBxAg), the presence of antibody to HBV x-protein antigen(HBxAg), the presence of HBV core-related antigen (HBcrAg), the presenceof antibody to HBV core-related antigen (anti-HBcrAg), HBV viral load,use of anti HBV medications, the presence of HBV DNA, the presence ofHBV mRNA, and the presence of HBV protein. Similarly, the term “HBVnegative” or “non-HBV infected,” used interchangeably herein, refers tothe HBV status of HCC patients, who are considered to have neither HBVinfection nor a history of it.

As used herein, the term “hepatocellular carcinoma (HCC) characterizedby hepatitis B virus (HBV) infection” is defined to be interchangeablewith the terms “HCC associated with HBV infection,” “HCC related to HBVinfection,” “HCC with a history of HBV infection,” “HBV positive HCC,”“HBV associated HCC,” “HBV related HCC,” or “HBV infected HCC.”

The term “likelihood” generally refers to an increase in the probabilityof an event. The term “likelihood” when used in reference to theeffectiveness of a cancer patient response generally contemplates anincreased probability that a cancer or tumor syndrome, or symptomthereof, will be lessened or decreased.

The term “predict” generally means to determine or tell in advance. Whenused to “predict” the effectiveness of a cancer treatment, for example,the term “predict” can mean that the likelihood of the outcome of thetreatment can be determined at the outset, before the treatment hasbegun, or before the treatment period has progressed substantially.

The terms “determining”, “measuring”, “evaluating”, “assessing,” and“assaying” as used herein generally refer to any form of measurement,and include determining whether an element is present or not. Theseterms include both quantitative and/or qualitative determinations.

In the context of HCC, inhibition may be assessed by inhibition ofdisease progression, inhibition of tumor growth, reduction of primarytumor, relief of tumor-related symptoms, inhibition of tumor secretedfactors (such as, for example, AFP), delayed appearance of primary orsecondary tumors, slowed development of primary or secondary tumors,decreased occurrence of primary or secondary tumors, slowed or decreasedseverity of secondary effects of disease, arrested tumor growth andregression of tumors, increased Time To Progression (TTP), increasedProgression Free Survival (PFS), increased Overall Survival (OS), amongothers. OS as used herein means the time from randomization (forexample, first dose date) until death from any cause, and is measured inthe intent-to-treat population. TTP as used herein means the time fromrandomization (for example, first dose date) until objective tumorprogression; TTP does not include deaths. As used herein, PFS means thetime from randomization (for example, first dose date) until objectivetumor progression or death. In one embodiment, PFS rates are computedusing the Kaplan-Meier estimates. In one embodiment, the survival rateis defined as the Kaplan-Meier estimated proportion of subjectssurviving at 6, 9, 12 months. As used herein, Disease control rate (DCR)means the percentage of subjects with complete (CR), or partial response(PR) or stable disease (SD). As used herein, Time To Response (TTR)means the time from randomization (for example, first dose date) to thefirst documentation of response of PR or better. As used herein,Duration of response (DOR) means the time from the time when criteriaare first met for CR/PR (whichever is first recorded) until the firstdate that recurrent or progressive disease is objectively documented.

In certain embodiments, the treatment of HCC may be assessed by ResponseEvaluation Criteria in Solid Tumors (RECIST 1.1) (see Thereasse et al.,J. National Cancer Institute, 2000, 92:205-216 and Eisenhauer et al.,European J. Cancer, 2009, 45:228-247). Overall responses for allpossible combinations of tumor responses in target and non-targetlesions with or without the appearance of new lesions are as follows:

Target Non-target New Overall lesions lesions lesions response CR CR NoCR CR Incomplete No PR response/SD PR Non-PD No PR SD Non-PD No SD PDAny Yes or no PD Any PD Yes or no PD Any Any Yes PD CR = completeresponse; PR = partial response; SD = stable disease; and PD =progressive disease.

With respect to the evaluation of target lesions, complete response (CR)is the disappearance of all target lesions, partial response (PR) is atleast a 30% decrease in the sum of the longest diameter of targetlesions, taking as reference the baseline sum longest diameter,progressive disease (PD) is at least a 20% increase in the sum of thelongest diameter of target lesions, taking as reference the smallest sumlongest diameter recorded since the treatment started or the appearanceof one or more new lesions, and stable disease (SD) is neithersufficient shrinkage to qualify for partial response nor sufficientincrease to qualify for progressive disease, taking as reference thesmallest sum longest diameter since the treatment started.

With respect to the evaluation of non-target lesions, CR is thedisappearance of all non-target lesions and normalization of tumormarker level, incomplete response/SD is the persistence of one or morenon-target lesion(s) and/or the maintenance of tumor marker level abovethe normal limits, and PD is the appearance of one or more new lesionsand/or unequivocal progression of existing non-target lesions.

In some embodiments, the treatment of HCC may also be assessed bymodified Response Evaluation Criteria in Solid Tumors (mRECIST for HCC)(see Lencioni et al. Semin Liver Dis. 2010 February; 30(1):52-60.

5.2 Compound 1

Provided herein are uses for the compound having the structure:

and having the name7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one,including pharmaceutically acceptable salts or tautomers thereof(collectively referred to herein as “Compound 1”).

Compound 1 can be prepared using reagents and methods known in the art,including the methods provided in U.S. Pat. No. 8,110,578, issued onFeb. 7, 2012; U.S. Pat. No. 8,569,494, issued on Oct. 29, 2013; and U.S.Pat. No. 9,359,364, issued on Jun. 7, 2016, the entire contents of eachof which are incorporated herein by reference.

As used herein “metabolite M1” refers to the compound having thestructure

and having the name1-((trans)-4-hydroxycyclohexyl)-7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]-pyrazin-2(1H)-one, or tautomers thereof.

It should be noted that if there is a discrepancy between a depictedstructure and a name given that structure, the depicted structure is tobe accorded more weight. In addition, if the stereochemistry of astructure or a portion of a structure is not indicated with, forexample, bold or dashed lines, the structure or portion of the structureis to be interpreted as encompassing all stereoisomers of it.

5.3 Methods of Use and Compound 1 for Use in Such Methods

Compound 1 as provided herein can be used in all methods providedherein. In one aspect, provided herein is a method for treating and/orpreventing HCC characterized by HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such a method for treating and/or preventing HCC characterized byHBV infection in a patient. In certain embodiments, provided herein is amethod for treating HCC characterized by HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for treating HCC characterized byHBV infection in a patient. In other embodiments, provided herein is amethod for preventing HCC characterized by HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for preventing HCC characterized byHBV infection in a patient, comprising administering an effective amountof Compound 1 to the patient having HCC characterized by HBV infection.In certain embodiments, the HCC characterized by HBV infection isunresectable HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating unresectable HCCcharacterized by HBV infection in a patient, comprising administering aneffective amount of Compound 1 to the patient having unresectable HCCcharacterized by HBV infection. Provided herein is Compound 1 for use insuch a method for treating unresectable HCC characterized by HBVinfection in a patient. In other embodiments, provided herein is amethod for preventing unresectable HCC characterized by HBV infection ina patient, comprising administering an effective amount of Compound 1 tothe patient having unresectable HCC characterized by HBV infection.Provided herein is Compound 1 for use in such a method for preventingunresectable HCC characterized by HBV infection in a patient.

In some embodiments, provided herein is a method for treating and/orpreventing HCC associated with HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC associated with HBV infection. Provided herein is Compound 1 for usein such a method for treating and/or preventing HCC associated with HBVinfection in a patient. In certain embodiments, provided herein is amethod for treating HCC associated with HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC associated with HBV infection. Provided herein isCompound 1 for use in such a method for treating HCC associated with HBVinfection in a patient. In other embodiments, provided herein is amethod for preventing HCC associated with HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC associated with HBV infection. Provided herein isCompound 1 for use in such a method for preventing HCC associated withHBV infection in a patient. In one embodiment, the HCC associated withHBV infection is unresectable HCC associated with HBV infection.

In some embodiments, provided herein is a method for treating and/orpreventing HCC related to HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC related to HBV infection. Provided herein is Compound 1 for use insuch a method for treating and/or preventing HCC related to HBVinfection in a patient. In certain embodiments, provided herein is amethod for treating HCC related to HBV infection in a patient,comprising administering an effective amount of Compound 1 to thepatient having HCC related to HBV infection. Provided herein is Compound1 for use in such a method for treating HCC related to HBV infection ina patient. In other embodiments, provided herein is a method forpreventing HCC related to HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC related to HBV infection. Provided herein is Compound 1 for use insuch a method for preventing HCC related to HBV infection in a patient.In one embodiment, the HCC related to HBV infection is unresectable HCCrelated to HBV infection.

In some embodiments, provided herein is a method for treating and/orpreventing HCC with a history of HBV infection in a patient, comprisingadministering an effective amount of Compound 1 to the patient havingHCC with a history of HBV infection. Provided herein is Compound 1 foruse in such a method for treating and/or preventing HCC with a historyof HBV infection in a patient. In certain embodiments, provided hereinis a method for treating HCC with a history of HBV infection in apatient, comprising administering an effective amount of Compound 1 tothe patient having HCC with a history of HBV infection. Provided hereinis Compound 1 for use in such a method for treating HCC with a historyof HBV infection in a patient. In other embodiments, provided herein isa method for preventing HCC with a history of HBV infection in apatient, comprising administering an effective amount of Compound 1 tothe patient having HCC with a history of HBV infection. Provided hereinis Compound 1 for use in such a method for preventing HCC with a historyof HBV infection in a patient. In one embodiment, the HCC with a historyof HBV infection is unresectable HCC with a history of HBV infection.

In some embodiments, provided herein is a method for treating and/orpreventing HBV positive HCC in a patient, comprising administering aneffective amount of Compound 1 to the patient having HBV positive HCC.Provided herein is Compound 1 for use in such a method for treatingand/or preventing HBV positive HCC in a patient. In certain embodiments,provided herein is a method for treating HBV positive HCC in a patient,comprising administering an effective amount of Compound 1 to thepatient having HBV positive HCC. Provided herein is Compound 1 for usein such a method for treating HBV positive HCC in a patient. In otherembodiments, provided herein is a method for preventing HBV positive HCCin a patient, comprising administering an effective amount of Compound 1to the patient having HBV positive HCC. Provided herein is Compound 1for use in such a method for preventing HBV positive HCC in a patient.In one embodiment, the HBV positive HCC is unresectable HBV positiveHCC.

In some embodiments, provided herein is a method for treating and/orpreventing HBV associated HCC in a patient, comprising administering aneffective amount of Compound 1 to the patient having HBV associated HCC.Provided herein is Compound 1 for use in such a method for treatingand/or preventing HBV associated HCC in a patient. In certainembodiments, provided herein is a method for treating HBV associated HCCin a patient, comprising administering an effective amount of Compound 1to the patient having HBV associated HCC. Provided herein is Compound 1for use in such a method for treating HBV associated HCC in a patient.In other embodiments, provided herein is a method for preventing HBVassociated HCC in a patient, comprising administering an effectiveamount of Compound 1 to the patient having HBV associated HCC. Providedherein is Compound 1 for use in such a method for reventing HBVassociated HCC in a patient. In one embodiment, the HBV associated HCCis unresectable HBV associated HCC.

In some embodiments, provided herein is a method for treating and/orpreventing HBV related HCC in a patient, comprising administering aneffective amount of Compound 1 to the patient having HBV related HCC.Provided herein is Compound 1 for use in such a method for treatingand/or preventing HBV related HCC in a patient. In certain embodiments,provided herein is a method for treating HBV related HCC in a patient,comprising administering an effective amount of Compound 1 to thepatient having HBV related HCC. Provided herein is Compound 1 for use insuch a method for treating HBV related HCC in a patient. In otherembodiments, provided herein is a method for preventing HBV related HCCin a patient, comprising administering an effective amount of Compound 1to the patient having HBV related HCC. Provided herein is Compound 1 foruse in such a method for preventing HBV related HCC in a patient. In oneembodiment, the HBV related HCC is unresectable HBV related HCC.

In some embodiments, provided herein is a method for treating and/orpreventing HBV infected HCC in a patient, comprising administering aneffective amount of Compound 1 to the patient having HBV infected HCC.Provided herein is Compound 1 for use in such a method for treatingand/or preventing HBV infected HCC in a patient. In certain embodiments,provided herein is a method for treating HBV infected HCC in a patient,comprising administering an effective amount of Compound 1 to thepatient having HBV infected HCC. Provided herein is Compound 1 for usein such a method for treating HBV infected HCC in a patient In otherembodiments, provided herein is a method for preventing HBV infected HCCin a patient, comprising administering an effective amount of Compound 1to the patient having HBV infected HCC. Provided herein is Compound 1for use in such a method for preventing HBV infected HCC in a patient.In one embodiment, the HBV infected HCC is unresectable HBV infectedHCC.

In another aspect, provided herein is a method for treating and/orpreventing HCC characterized by HBV infection in a patient, comprisingscreening a biological test sample from the patient for HBV infection,and administering an effective amount of Compound 1 to the patienthaving HCC characterized by HBV infection. Provided herein is Compound 1for use in such a method for treating and/or preventing HCCcharacterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. In certainembodiments, provided herein is a method for treating HCC characterizedby HBV infection in a patient, comprising screening a biological testsample from the patient for HBV infection, and administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such a methodfor treating HCC characterized by HBV infection in a patient, whereinthe method comprises screening a biological test sample from the patientfor HBV infection, and administering an effective amount of Compound 1to the patient having HCC characterized by HBV infection. In otherembodiments, provided herein is a method for preventing HCCcharacterized by HBV infection in a patient, comprising screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such a method for preventing HCC characterized by HBV infectionin a patient, wherein the method comprises screening a biological testsample from the patient for HBV infection, and administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection.

In certain embodiments, the HCC characterized by HBV infection isunresectable HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating unresectable HCCcharacterized by HBV infection in a patient, comprising screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Provided herein isCompound 1 for use in such a method for treating unresectable HCCcharacterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having unresectable HCC characterized by HBV infection. In yetother embodiments, provided herein is a method for preventingunresectable HCC characterized by HBV infection in a patient, comprisingscreening a biological test sample from the patient for HBV infection,and administering an effective amount of Compound 1 to the patienthaving unresectable HCC characterized by HBV infection. Provided hereinis Compound 1 for use in such a method for preventing unresectable HCCcharacterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having unresectable HCC characterized by HBV infection.

In certain embodiments, the HCC characterized by HBV infection ispreviously untreated HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating previouslyuntreated HCC characterized by HBV infection in a patient, comprisingscreening a biological test sample from the patient for HBV infection,and administering an effective amount of Compound 1 to the patienthaving previously untreated HCC characterized by HBV infection. Providedherein is Compound 1 for use in such a method for treating previouslyuntreated HCC characterized by HBV infection in a patient, wherein themethod comprises screening a biological test sample from the patient forHBV infection, and administering an effective amount of Compound 1 tothe patient having previously untreated HCC characterized by HBVinfection. In other embodiments, the HCC characterized by HBV infectionis previously treated HCC characterized by HBV infection. Thus, in someembodiments, provided herein is a method for treating previously treatedHCC characterized by HBV infection in a patient, comprising screening abiological test sample from the patient for HBV infection, andadministering an effective amount of Compound 1 to the patient havingpreviously treated HCC characterized by HBV infection. Provided hereinis Compound 1 for use in such a method for treating previously treatedHCC characterized by HBV infection in a patient, wherein the methodcomprises screening a biological test sample from the patient for HBVinfection, and administering an effective amount of Compound 1 to thepatient having previously treated HCC characterized by HBV infection. Insome embodiments, the HCC characterized by HBV infection is previouslytreated with at least one therapy. In some such embodiments, the HCCcharacterized by HBV infection was previously treated at least withsorafenib and/or chemotherapy. In one embodiment, the HCC characterizedby HBV infection is previously treated with one therapy. In anotherembodiment, the HCC characterized by HBV infection is previously treatedwith two therapies. In still another embodiment, the HCC characterizedby HBV infection is previously treated with three therapies. In stillother embodiments, the HCC characterized by HBV infection is previouslytreated with four therapies. In some such embodiments, the HCCcharacterized by HBV infection is previously treated HCC, wherein theprevious treatment comprises sorafenib and/or chemotherapy. In some suchembodiments, the HCC characterized by HBV infection is previouslytreated HCC, wherein the previous treatment comprises at least sorafeniband/or chemotherapy. In some such embodiments, the HCC characterized byHBV infection is previously treated HCC, wherein the previous treatmentcomprises sorafenib. In some other such embodiments, the HCCcharacterized by HBV infection is previously treated HCC, wherein theprevious treatment comprises at least chemotherapy.

In yet another aspect, provided herein is a method for selecting apatient having HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having HCC for Compound 1 treatmentif HBV infection is determined in the sample. In certain embodiments,the method further comprises a step d) administering an effective amountof Compound 1 to the patient having HCC characterized by HBV infection.Thus, in some embodiments, provided herein is a method for selecting apatient having HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having HCC for Compound 1 treatmentif HBV infection is determined in the sample; and d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, further provided herein is Compound 1 for use insuch a method for selecting a patient having HCC for Compound 1treatment, wherein the method comprises a) obtaining a biological testsample from the patient; b) analyzing the sample for HBV infection; c)selecting the patient having HCC for Compound 1 treatment if HBVinfection is determined in the sample; and d) administering an effectiveamount of Compound 1 to the patient having HCC characterized by HBVinfection.

In certain embodiments, the HCC is unresectable HCC. In someembodiments, provided herein is a method for selecting a patient havingunresectable HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having unresectable HCC for Compound1 treatment if HBV infection is determined in the sample. In otherembodiments, provided herein is a method for selecting a patient havingunresectable HCC for Compound 1 treatment, comprising a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) selecting the patient having unresectable HCC for Compound1 treatment if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Thus, further providedherein is Compound 1 for use in such a method for selecting a patienthaving unresectable HCC for Compound 1 treatment, wherein the methodcomprises a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) selecting the patient havingunresectable HCC for Compound 1 treatment if HBV infection is determinedin the sample; and d) administering an effective amount of Compound 1 tothe patient having unresectable HCC characterized by HBV infection.

In still another aspect, provided herein is a method for predictingresponse to treatment with Compound 1 in a patient having HCC, themethod comprising: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's HCC if HBV infection is determined in the sample. In certainembodiments, the method further comprises a step d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, in some embodiments, provided herein is a methodfor predicting response to treatment with Compound 1 in a patient havingHCC, the method comprising: a) obtaining a biological test sample fromthe patient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's HCC if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Thus, further provided herein isCompound 1 for use in such a method for predicting response to treatmentwith Compound 1 in a patient having HCC, wherein the method comprises:a) obtaining a biological test sample from the patient; b) analyzing thesample for HBV infection; c) predicting an increased likelihood ofresponse to the Compound 1 treatment of the patient's HCC if HBVinfection is determined in the sample; and d) administering an effectiveamount of Compound 1 to the patient having HCC characterized by HBVinfection.

In certain embodiments, the HCC is unresectable HCC. In someembodiments, provided herein is a method for predicting response totreatment with Compound 1 in a patient having unresectable HCC, themethod comprising: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's unresectable HCC if HBV infection is determined in the sample.In other embodiments, provided herein is a method for predictingresponse to treatment with Compound 1 in a patient having unresectableHCC, the method comprising: a) obtaining a biological test sample fromthe patient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of response to the Compound 1 treatment of thepatient's unresectable HCC if HBV infection is determined in the sample;and d) administering an effective amount of Compound 1 to the patienthaving unresectable HCC characterized by HBV infection. Thus, furtherprovided herein is Compound 1 for use in such a method for predictingresponse to treatment with Compound 1 in a patient having unresectableHCC, wherein the method comprises: a) obtaining a biological test samplefrom the patient; b) analyzing the sample for HBV infection; c)predicting an increased likelihood of response to the Compound 1treatment of the patient's unresectable HCC if HBV infection isdetermined in the sample; and d) administering an effective amount ofCompound 1 to the patient having unresectable HCC characterized by HBVinfection.

In another aspect, provided herein is a method for predictingtherapeutic efficacy of Compound 1 in a patient having HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient's HCC ifHBV infection is determined in the sample. In certain embodiments, themethod further comprises a step d) administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection.Thus, in some embodiments, provided herein is a method for predictingtherapeutic efficacy of Compound 1 in a patient having HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient's HCC ifHBV infection is determined in the sample; and d) administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Thus, further provided herein is Compound 1 for use insuch a method for predicting therapeutic efficacy of Compound 1 in apatient having HCC, wherein the method comprises: a) obtaining abiological test sample from the patient; b) analyzing the sample for HBVinfection; c) predicting an increased likelihood of therapeutic efficacyof Compound 1 in the patient's HCC if HBV infection is determined in thesample; and d) administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection.

In certain embodiments, the HCC is unresectable HCC. In someembodiments, provided herein is a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient'sunresectable HCC if HBV infection is determined in the sample. In otherembodiments, provided herein is a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, the methodcomprising: a) obtaining a biological test sample from the patient; b)analyzing the sample for HBV infection; c) predicting an increasedlikelihood of therapeutic efficacy of Compound 1 in the patient'sunresectable HCC if HBV infection is determined in the sample; and d)administering an effective amount of Compound 1 to the patient havingunresectable HCC characterized by HBV infection. Thus, further providedherein is Compound 1 for use in such a method for predicting therapeuticefficacy of Compound 1 in a patient having unresectable HCC, wherein themethod comprises: a) obtaining a biological test sample from thepatient; b) analyzing the sample for HBV infection; c) predicting anincreased likelihood of therapeutic efficacy of Compound 1 in thepatient's unresectable HCC if HBV infection is determined in the sample;and d) administering an effective amount of Compound 1 to the patienthaving unresectable HCC characterized by HBV infection.

In various methods provided herein, HBV infection is determined by atleast one of the variables selected from the group consisting of:patient history of HBV, prior or current treatment for HBV, cirrhosisattributed to HBV, the presence of HBV proteins or antigens, thepresence of antibodies to HBV proteins or antigens, HBV viral load, andthe presence of HBV DNA. In one embodiment, HBV infection is determinedby patient history of HBV. In another embodiment, HBV infection isdetermined by prior treatment for HBV. In yet another embodiment, HBVinfection is determined by current treatment for HBV. In still anotherembodiment, HBV infection is determined by cirrhosis attributed to HBV.In another embodiment, HBV infection is determined by the presence ofHBV proteins or antigens. In another embodiment, HBV infection isdetermined by the presence of antibodies to HBV proteins or antigens. Inyet another embodiment, HBV infection is determined by HBV viral load.In yet another embodiment, HBV infection is determined by the presenceof HBV DNA. In certain embodiments, HBV infection is determined by two,three, four, five, six, seven, or all of the variables selected from thegroup consisting of: patient history of HBV, prior treatment for HBV,current treatment for HBV, cirrhosis attributed to HBV, the presence ofHBV proteins, the presence of HBV antigens, the presence of antibodiesto HBV proteins, the presence of antibodies to HBV antigens, HBV viralload, and the presence of HBV DNA.

In another embodiment, in various methods provided herein, HBV infectionis determined by at least one of the variables selected from the groupconsisting of: the presence of HBsAg, the presence of HBcAg, thepresence of HBeAg, the presence of HBxAg, the presence of HBcrAg, thepresence of anti-HBsAg, the presence of anti-HBcAg, the presence ofanti-HBeAg, the presence of anti-HBxAg, the presence of anti-HBcrAg, HBVviral load, the use of HBV medications, the presence of HBV DNA, thepresence of HBV mRNA, and the presence of HBV protein. In oneembodiment, HBV infection is determined by the presence of HBsAg. Inanother embodiment, HBV infection is determined by the presence ofHBcAg. In another embodiment, HBV infection is determined by thepresence of HBeAg. In another embodiment, HBV infection is determined bythe presence of HBxAg. In another embodiment, HBV infection isdetermined by the presence of HBcrAg. In yet another embodiment, HBVinfection is determined by the presence of anti-HBsAg. In yet anotherembodiment, HBV infection is determined by the presence of anti-HBcAg.In yet another embodiment, HBV infection is determined by the presenceof anti-HBeAg. In yet another embodiment, HBV infection is determined bythe presence of anti-HBxAg. In yet another embodiment, HBV infection isdetermined by the presence of anti-HBcrAg. In still another embodiment,HBV infection is determined by HBV viral load. In one embodiment, HBVinfection is determined by the use of HBV medications. In oneembodiment, HBV infection is determined by the presence of HBV DNA. Inanother embodiment, HBV infection is determined by the presence of HBVmRNA. In yet another embodiment, HBV infection is determined by thepresence of HBV protein. In another embodiment, HBV infection is relatedto the lack of immunization. In some embodiments, HBV infection isdetermined by two, three, four, five, six, seven, eight, nine, ten, orall of the variables selected from the group consisting of: the presenceof HBsAg, the presence of HBcAg, the presence of HBeAg, the presence ofHBxAg, the presence of HBcrAg, the presence of anti-HBsAg, the presenceof anti-HBcAg, the presence of anti-HBeAg, the presence of anti-HBxAg,the presence of anti-HBcrAg, HBV viral load, the use of HBV medications,the presence of HBV DNA, the presence of HBV mRNA, and the presence ofHBV protein.

The HBV DNA detected can be any fragment of the HBV genome, whetherencoding an HBV protein or not. The HBV mRNA detected can be anyfragment of the HBV mRNA pool. The HBV protein detected can be any HBVprotein or fragments thereof.

In some embodiments, the HBV DNA is the DNA encoding HBxAg or fragmentsthereof. In certain embodiments, the HBV mRNA is the mRNA of HBxAg orfragments thereof. In other embodiments, the HBV protein is HBxAg orfragments thereof.

In some embodiments, the HBV DNA is the DNA encoding HBsAg or fragmentsthereof. In certain embodiments, the HBV mRNA is the mRNA of HBsAg orfragments thereof. In other embodiments, the HBV protein is HBsAg orfragments thereof.

In some embodiments, the HBV DNA is the DNA encoding HBcAg or fragmentsthereof. In certain embodiments, the HBV mRNA is the mRNA of HBcAg orfragments thereof. In other embodiments, the HBV protein is HBcAg orfragments thereof.

In some embodiments, the HBV DNA is the DNA encoding HBeAg or fragmentsthereof. In certain embodiments, the HBV mRNA is the mRNA of HBeAg orfragments thereof. In other embodiments, the HBV protein is HBeAg orfragments thereof.

In some embodiments, the HBV DNA is the DNA encoding HBerAg or fragmentsthereof. In certain embodiments, the HBV mRNA is the mRNA of HBcrAg orfragments thereof. In other embodiments, the HBV protein is HBcrAg orfragments thereof.

In various methods provided herein, HBV infection can be detected in abiological sample from a patient. In some embodiments, the biologicalsample is a sample from serum, plasma, blood, dried blood/plasma spots,hepatocytes, primary tumor, or sites of metastasis of HCC, including butnot limited to, lungs, lymph nodes, adrenal glands, bones, peritoneum,portal vein, brain, saliva, parotid tissue, etc. In some embodiments,HBV infection is detected by serological methods. In other embodiments,HBV infection is detected by molecular methods. Serological methodsinclude but are not limited to enzyme linked immunosorbent assay(ELISA), chemiluminescent enzyme immunoassay or chemiluminescentimmunoassay (CLEIA or CLIA), time resolved fluroimmunoassay (TRFIA),chemiluminescent microparticle immunoassay (CMIA),electro-chemiluminescent immunoassay (ECLIA), and goldenimmunochromatographic assay (GICA). Molecular methods include but arenot limited to nucleic acid hybridization, nucleic acid amplification(e.g., PCR, real time PCR, multiplex PCR, and branched DNA assay),sequencing, and enzymatic digestion of nucleic acids. Both serologicaland molecular methods can be conducted on automated systems (such asAbbott AxSYM, Roche Elecsys, Abbott Architect, version 2.0 ofCobasAmpliPrep/CobasTaqMan (CAP/CTM)).

In certain embodiments, the various assays detect at least one biomarkerof HBV selected from the group consisting of HBsAg, anti-HBsAg, HBcAg,anti-HBcAg, HBeAg, anti-HBeAg, HBxAg, anti-HBxAg, HBcrAg, andanti-HBcrAg. In one embodiment, the biomarker is HBsAg. In anotherembodiment, the biomarker is anti-HBsAg. In yet another embodiment, thebiomarker is HBcAg. In still another embodiment, the biomarker isanti-HBcAg. In one embodiment, the biomarker is HBeAg. In anotherembodiment, the biomarker is anti-HBeAg. In one embodiment, thebiomarker is HBxAg. In still another embodiment, the biomarker isanti-HBxAg. In still another embodiment, the biomarker is HBerAg. Inanother embodiment, the biomarker is anti-HBcrAg. In yet anotherembodiment, the various assays detect two, three, four, five, six,seven, eight, nine or all biomarkers of HBV selected from the groupconsisting of HBsAg, anti-HBsAg, HBcAg, anti-HBcAg, HBeAg, anti-HBeAg,HBxAg, anti-HBxAg, HBcrAg, and anti-HBcrAg.

In various methods provided herein, Compound 1 is administered incombination with a second therapeutic agent to the HCC patientcharacterized by HBV infection. In one embodiment, the secondtherapeutic agent is sorafenib. In another embodiment, the secondtherapeutic agent is3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione(Compound 2). In yet another embodiment, the second therapeutic agent isan immune check point inhibitor (e.g., CTLA-4 inhibitor, PD-1 inhibitor,PD-L1 inhibitor, PD-L2 inhibitor, LAG-3 inhibitor, TIM3 inhibitor, IDOinhibitor, OX40 agonist, GITR agonist, CD137 agonist, CD40 agonist,recombinant human interleukin-15). In still another embodiment, Compound1 is administered in combination with a second and a third therapeuticagents to the HCC patient characterized by HBV infection. In someembodiment, the second and the third therapeutic agents are selectedfrom the group consisting of sorafenib, Compound 2, and an immune checkpoint inhibitor (e.g., PD-1 inhibitor). In one embodiment, the secondand the third therapeutic agents are sorafenib and Compound 2. Inanother embodiment, the second and the third therapeutic agents aresorafenib and an immune check point inhibitor (e.g., PD-1 inhibitor). Inyet another embodiment, the second and the third therapeutic agents areCompound 2 and an immune check point inhibitor (e.g., PD-1 inhibitor).In still another embodiment, the second and the third therapeutic agentsare two different immune check point inhibitors (e.g., PD-1 inhibitorand CTLA-4 inhibitor).

In one embodiment, the checkpoint inhibitor is a CTLA-4 inhibitor. Inone embodiment, the CTLA-4 inhibitor is an anti-CTLA-4 antibody.Examples of anti-CTLA-4 antibodies include, but are not limited to,those described in U.S. Pat. Nos. 5,811,097; 5,811,097; 5,855,887;6,051,227; 6,207,157; 6,682,736; 6,984,720; and 7,605,238, all of whichare incorporated herein in their entireties. In one embodiment, theanti-CTLA-4 antibody is tremelimumab (also known as ticilimumab orCP-675,206). In another embodiment, the anti-CTLA-4 antibody isipilimumab (also known as MDX-010 or MDX-101). Ipilimumab is a fullyhuman monoclonal IgG antibody that binds to CTLA-4. Ipilimumab ismarketed under the trade name Yervoy™.

In one embodiment, the checkpoint inhibitor is a PD-1/PD-L1 inhibitor.Examples of PD-1/PD-L1 inhibitors include, but are not limited to, thosedescribed in U.S. Pat. Nos. 7,488,802; 7,943,743; 8,008,449; 8,168,757;8,217,149, and PCT Patent Application Publication Nos. WO2003042402,WO2008156712, WO2010089411, WO2010036959, WO2011066342, WO2011159877,WO2011082400, and WO2011161699, all of which are incorporated herein intheir entireties.

In one embodiment, the checkpoint inhibitor is a PD-1 inhibitor. In oneembodiment, the PD-1 inhibitor is an anti-PD-1 antibody. In oneembodiment, the anti-PD-1 antibody is BGB-A317, nivolumab (also known asONO-4538, BMS-936558, or MDX1106) or pembrolizumab (also known asMK-3475, SCH 900475, or lambrolizumab). In one embodiment, the anti-PD-1antibody is nivolumab. Nivolumab is a human IgG4 anti-PD-1 monoclonalantibody, and is marketed under the trade name Opdivo™. In a specificembodiment, Compound 1 is administered in combination with nivolumab tothe patient having HCC characterized by HBV infection. Thus, provided isa method of treating HCC characterized by HBV infection, wherein themethod comprises administering an effective amount of Compound 1 incombination with nivolumab to said patient. Provided herein is Compound1 for use in a method of treating HCC characterized by HBV infection,wherein the method comprises administering an effective amount ofCompound 1 in combination with nivolumab to said patient. In a specificembodiment, Compound 1 is administered in combination with nivolumab tothe patient having HCC characterized by HBV infection, wherein the HCCis previously treated with at least one therapy. Thus, provided is amethod of treating HCC characterized by HBV infection previously treatedwith at least one therapy, wherein the method comprises administering aneffective amount of Compound 1 in combination with nivolumab to saidpatient. In one such embodiment, the previous therapy comprisessorafenib or chemotherapy. In one such embodiment, the previous therapycomprises sorafenib and chemotherapy. Provided herein is Compound 1 foruse in a method of treating HCC characterized by HBV infectionpreviously treated with at least one therapy, wherein the methodcomprises administering an effective amount of Compound 1 in combinationwith nivolumab to said patient. In a specific embodiment, Compound 1 isadministered in combination with nivolumab to the patient having HCCcharacterized by HBV infection, wherein the HCC is previously treatedwith sorafenib. Thus, provided is a method of treating HCC characterizedby HBV infection previously treated with sorafenib, wherein the methodcomprises administering an effective amount of Compound 1 in combinationwith nivolumab to said patient. Provided herein is Compound 1 for use ina method of treating HCC characterized by HBV infection previouslytreated with sorafenib, wherein the method comprises administering aneffective amount of Compound 1 in combination with nivolumab to saidpatient. In a specific embodiment, Compound 1 is administered incombination with nivolumab to the patient having HCC characterized byHBV infection, wherein the HCC is previously treated with chemotherapy.Thus, provided is a method of treating HCC characterized by HBVinfection previously treated with chemotherapy, wherein the methodcomprises administering an effective amount of Compound 1 in combinationwith nivolumab to said patient. Provided herein is Compound 1 for use ina method of treating HCC characterized by HBV infection previouslytreated with chemotherapy, wherein the method comprises administering aneffective amount of Compound 1 in combination with nivolumab to saidpatient.

In another embodiment, the anti-PD-1 antibody is pembrolizumab.Pembrolizumab is a humanized monoclonal IgG4 antibody and is marketedunder the trade name Keytruda™. In yet another embodiment, the anti-PD-1antibody is CT-011, a humanized antibody. In yet another embodiment, theanti-PD-1 antibody is AMP-224, a fusion protein. In another embodiment,the PD-1 antibody is BGB-A317. BGB-A317 is a monoclonal antibody inwhich the ability to bind Fc gamma receptor I is specifically engineeredout, and which has a unique binding signature to PD-1 with high affinityand superior target specificity.

In one embodiment, the checkpoint inhibitor is a PD-L1 inhibitor. In oneembodiment, the PD-L1 inhibitor is an anti-PD-L1 antibody. In oneembodiment, the anti-PD-L1 antibody is MEDI4736 (durvalumab). In anotherembodiment, the anti-PD-L1 antibody is BMS-936559 (also known asMDX-1105-01). In yet another embodiment, the PD-L1 inhibitor isatezolizumab (also known as MPDL3280A, and Tecentriq®).

In one embodiment, the checkpoint inhibitor is a PD-L2 inhibitor. In oneembodiment, the PD-L2 inhibitor is an anti-PD-L2 antibody. In oneembodiment, the anti-PD-L2 antibody is rHIgM12B7A.

In one embodiment, the checkpoint inhibitor is a lymphocyte activationgene-3 (LAG-3) inhibitor. In one embodiment, the LAG-3 inhibitor isIMP321, a soluble Ig fusion protein (Brignone et al., J. Immunol., 2007,179, 4202-4211). In another embodiment, the LAG-3 inhibitor isBMS-986016.

In one embodiment, the checkpoint inhibitor is a B7 inhibitor. In oneembodiment, the B7 inhibitor is a B7-H3 inhibitor or a B7-H4 inhibitor.In one embodiment, the B7-H3 inhibitor is MGA271, an anti-B7-H3 antibody(Loo et al., Clin. Cancer Res., 2012, 3834).

In one embodiment, the checkpoint inhibitor is a TIM3 (T-cellimmunoglobulin domain and mucin domain 3) inhibitor (Fourcade et al., J.Exp. Med., 2010, 207, 2175-86; Sakuishi et al., J. Exp. Med., 2010, 207,2187-94).

In one embodiment, the checkpoint inhibitor is an OX40 (CD134) agonist.In one embodiment, the checkpoint inhibitor is an anti-OX40 antibody. Inone embodiment, the anti-OX40 antibody is anti-OX-40. In anotherembodiment, the anti-OX40 antibody is MEDI6469.

In one embodiment, the checkpoint inhibitor is a GITR agonist. In oneembodiment, the checkpoint inhibitor is an anti-GITR antibody. In oneembodiment, the anti-GITR antibody is TRX518.

In one embodiment, the checkpoint inhibitor is a CD137 agonist. In oneembodiment, the checkpoint inhibitor is an anti-CD137 antibody. In oneembodiment, the anti-CD137 antibody is urelumab. In another embodiment,the anti-CD137 antibody is PF-05082566.

In one embodiment, the checkpoint inhibitor is a CD40 agonist. In oneembodiment, the checkpoint inhibitor is an anti-CD40 antibody. In oneembodiment, the anti-CD40 antibody is CF-870,893.

In one embodiment, the checkpoint inhibitor is recombinant humaninterleukin-15 (rhIL-15).

In one embodiment, the checkpoint inhibitor is an IDO inhibitor. In oneembodiment, the IDO inhibitor is INCB024360. In another embodiment, theIDO inhibitor is indoximod.

Examples of such additional agents include, but are not limited to:Abraxane® (paclitaxel protein-bound particles for injectable suspension(albuin-bound)); ace-11; acivicin; aclarubicin; acodazole hydrochloride;acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantroneacetate; amrubicin; amsacrine; anastrozole; anthramycin; asparaginase;asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa;bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin;bleomycin sulfate; brequinar sodium; bropirimine; busulfan;cactinomycin; calusterone; caracemide; carbetimer; carboplatin;carmustine; carubicin hydrochloride; carzelesin; cedefingol; celecoxib(COX-2 inhibitor); chlorambucil; cirolemycin; cisplatin; cladribine;crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine;dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin;dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin;doxorubicin hydrochloride; droloxifene; droloxifene citrate;dromostanolone propionate; duazomycin; edatrexate; eflornithinehydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine;epirubicin hydrochloride; erbulozole; esorubicin hydrochloride;estramustine; estramustine phosphate sodium; etanidazole; etoposide;etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine;fenretinide; floxuridine; fludarabine phosphate; fluorouracil;flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabinehydrochloride; herceptin; hydroxyurea; idarubicin hydrochloride;ifosfamide; ilmofosine; iproplatin; irinotecan; irinotecanhydrochloride; lanreotide acetate; lapatinib; letrozole; leuprolideacetate; liarozole hydrochloride; lometrexol sodium; lomustine;losoxantrone hydrochloride; masoprocol; maytansine; mechlorethaminehydrochloride; megestrol acetate; melengestrol acetate; melphalan;menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine;meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin;mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolicacid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel;pegaspargase; peliomycin; pentamustine; peplomycin sulfate;perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride;plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine;procarbazine hydrochloride; puromycin; puromycin hydrochloride;pyrazofurin; riboprine; romidepsin; safingol; safingol hydrochloride;semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermaniumhydrochloride; spiromustine; spiroplatin; stem cell treatments such asPDA-001; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalansodium; taxotere; tegafur; teloxantrone hydrochloride; temoporfin;teniposide; teroxirone; testolactone; thiamiprine; thioguanine;thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestoloneacetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate;triptorelin; tubulozole hydrochloride; uracil mustard; uredepa;vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate;vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate;vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate;vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicinhydrochloride.

Other examples include, but are not limited to: 20-epi-1,25dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin;acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists;altretamine; ambamustine; amidox; amifostine; aminolevulinic acid;amrubicin; amsacrine; anagrelide; anastrozole; andrographolide;angiogenesis inhibitors; antagonist D; antagonist G; antarelix;anti-dorsalizing morphogenetic protein-1; antiandrogen, prostaticcarcinoma; antiestrogen; antineoplaston; antisense oligonucleotides;aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators;apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3;azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol;batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine;beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid;b-FGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine;bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane;buthionine sulfoximine; calcipotriol; calphostin C; camptothecinderivatives; capecitabine; carboxamide-amino-triazole;carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor;carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropinB; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost;cis-porphyrin; cladribine; clomifene analogues; clotrimazole;collismycin A; collismycin B; combretastatin A4; combretastatinanalogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8;cryptophycin A derivatives; curacin A; cyclopentanthraquinones;cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor;cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin;dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine;dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel;docosanol; dolasetron; doxifluridine; doxorubicin; droloxifene;dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine;edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride;estramustine analogue; estrogen agonists; estrogen antagonists;etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine;fenretinide; filgrastim; finasteride; flavopiridol; flezelastine;fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex;formestane; fostriecin; fotemustine; gadolinium texaphyrin; galliumnitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine;glutathione inhibitors; hepsulfam; heregulin; hexamethylenebisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene;idramantone; ilmofosine; ilomastat; imatinib (e.g., GLEEVEC®),imiquimod; immunostimulant peptides; insulin-like growth factor-1receptor inhibitor; interferon agonists; interferons; interleukins;iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine;isobengazole; isohomohalicondrin B; itasetron; jasplakinolide;kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin;lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemiainhibiting factor; leukocyte alpha interferon;leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole;linear polyamine analogue; lipophilic disaccharide peptide; lipophilicplatinum compounds; lissoclinamide 7; lobaplatin; lombricine;lometrexol; lonidamine; losoxantrone; loxoribine; lurtotecan; lutetiumtexaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A;marimastat; masoprocol; maspin; matrilysin inhibitors; matrixmetalloproteinase inhibitors; menogaril; merbarone; meterelin;methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine;mirimostim; mitoguazone; mitolactol; mitomycin analogues; mitonafide;mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene;molgramostim; Erbitux, human chorionic gonadotrophin; monophosphoryllipid A+myobacterium cell wall sk; mopidamol; mustard anticancer agent;mycaperoxide B; mycobacterial cell wall extract; myriaporone;N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip;naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;nemorubicin; neridronic acid; nilutamide; nisamycin; nitric oxidemodulators; nitroxide antioxidant; nitrullyn; oblimersen (GENASENSE®);O⁶-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone;ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin;osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues;paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase;peldesine; pentosan polysulfate sodium; pentostatin; pentrozole;perflubron; perfosfamide; perillyl alcohol; phenazinomycin;phenylacetate; phosphatase inhibitors; picibanil; pilocarpinehydrochloride; pirarubicin; piritrexim; placetin A; placetin B;plasminogen activator inhibitor; platinum complex; platinum compounds;platinum-triamine complex; porfimer sodium; porfiromycin; prednisone;propyl bis-acridone; prostaglandin J2; proteasome inhibitors; proteinA-based immune modulator; protein kinase C inhibitor; protein kinase Cinhibitors, microalgal; protein tyrosine phosphatase inhibitors; purinenucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists;raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors;ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re186 etidronate; rhizoxin; ribozymes; RII retinamide; rohitukine;romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin;SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;senescence derived inhibitor 1; sense oligonucleotides; signaltransduction inhibitors; sizofiran; sobuzoxane; sodium borocaptate;sodium phenylacetate; solverol; somatomedin binding protein; sonermin;sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin1; squalamine; stipiamide; stromelysin inhibitors; sulfinosine;superactive vasoactive intestinal peptide antagonist; suradista;suramin; swainsonine; tallimustine; tamoxifen methiodide; tauromustine;tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomeraseinhibitors; temoporfin; teniposide; tetrachlorodecaoxide; tetrazomine;thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic;thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroidstimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocenebichloride; topsentin; toremifene; translation inhibitors; tretinoin;triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron;turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors;ubenimex; urogenital sinus-derived growth inhibitory factor; urokinasereceptor antagonists; vapreotide; variolin B; velaresol; veramine;verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole;zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

In one embodiment, the patient has received at least one prior therapyfor HCC. In another embodiment, the patient has received one priortherapy for HCC. In yet another embodiment, the patient has received twoprior therapies for HCC. In still another embodiment, the patient hasreceived three prior therapies for HCC. In another embodiment, thepatient has received no prior therapy for HCC. In some embodiments, theprior therapy is a systemic therapy (e.g., drug treatment). In otherembodiments, the prior therapy is a locoregional therapy (e.g.,radiotherapy).

In one embodiment, provided herein are methods for preventing ordelaying a RECIST (for example, RECIST 1.1) of PD in a patient havingHCC characterized by HBV infection, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such methodsfor preventing or delaying a RECIST (for example, RECIST 1.1) of PD in apatient having HCC characterized by HBV infection. In one embodiment,provided herein are methods for preventing or delaying a mRECIST for HCCof PD in a patient having HCC characterized by HBV infection, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such methods for preventing or delaying a mRECIST for HCC of PDin a patient having HCC characterized by HBV infection. In oneembodiment, the prevention or delaying of PD is characterized orachieved by a change in overall size of the target lesions, for example,between −30% and −20% compared to pre-treatment. In another embodiment,the change in size of the target lesions is a reduction in overall sizeof more than 30%, for example, more than 50% reduction in target lesionsize compared to pre-treatment. In another, the prevention ischaracterized or achieved by a reduction in size or a delay inprogression of non-target lesions compared to pre-treatment. In oneembodiment, the prevention is achieved or characterized by a reductionin the number of target lesions compared to pre-treatment. In another,the prevention is achieved or characterized by a reduction in the numberor quality of non-target lesions compared to pre-treatment. In oneembodiment, the prevention is achieved or characterized by the absenceor the disappearance of target lesions compared to pre-treatment. Inanother, the prevention is achieved or characterized by the absence orthe disappearance of non-target lesions compared to pre-treatment. Inanother embodiment, the prevention is achieved or characterized by theprevention of new lesions compared to pre-treatment. In yet anotherembodiment, the prevention is achieved or characterized by theprevention of clinical signs or symptoms of disease progression comparedto pre-treatment, such as HCC-related cachexia or increased pain.

In certain embodiments, provided herein are methods for decreasing thesize of a target lesion in a patient having HCC characterized by HBVinfection compared to pre-treatment, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such methodsfor decreasing the size of a target lesion in a patient having HCCcharacterized by HBV infection compared to pre-treatment.

In certain embodiments, provided herein are methods for decreasing thesize of a non-target lesion in a patient having HCC characterized by HBVinfection compared to pre-treatment, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such methodsfor decreasing the size of a non-target lesion in a patient having HCCcharacterized by HBV infection compared to pre-treatment.

In certain embodiments, provided herein are methods for achieving areduction in the number of target lesions in a patient having HCCcharacterized by HBV infection compared to pre-treatment, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such methods for achieving a reduction in the number of targetlesions in a patient having HCC characterized by HBV infection comparedto pre-treatment.

In certain embodiments, provided herein are methods for achieving areduction in the number of non-target lesions in a patient having HCCcharacterized by HBV infection compared to pre-treatment, comprisingadministering an effective amount Compound 1 to the patient having HCCcharacterized by HBV infection. Provided herein is Compound 1 for use insuch methods for achieving a reduction in the number of non-targetlesions in a patient having HCC characterized by HBV infection comparedto pre-treatment.

In certain embodiments, provided herein are methods for achieving anabsence of all target lesions in a patient having HCC characterized byHBV infection, comprising administering an effective amount of Compound1 to the patient having HCC characterized by HBV infection. Providedherein is Compound 1 for use in such methods for achieving an absence ofall target lesions in a patient having HCC characterized by HBVinfection.

In certain embodiments, provided herein are methods for achieving anabsence of all non-target lesions in a patient having HCC characterizedby HBV infection, comprising administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection.Provided herein is Compound 1 for use in such methods for achieving anabsence of all non-target lesions in a patient having HCC characterizedby HBV infection.

In certain embodiments, provided herein are methods for treating HCCcharacterized by HBV infection, the methods comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection, wherein the treatment results in a CR, PR or SD, asdetermined by RECIST (for example, RECIST 1.1 or mRECIST for HCC).Provided herein is Compound 1 for use in such methods for treating HCCcharacterized by HBV infection, wherein the methods compriseadministering an effective amount of Compound 1 to a patient having HCCcharacterized by HBV infection, wherein the treatment results in a CR,PR or SD, as determined by RECIST (for example, RECIST 1.1 or mRECISTfor HCC).

In certain embodiments, provided herein are methods for treating HCCcharacterized by HBV infection, the methods comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection, wherein the treatment results in a reduction in targetlesion size, a reduction in non-target lesion size, a reduction intarget lesion number, a reduction in non-target lesion number, and/orthe absence of all target and/or non-target lesions, compared topre-treatment. Provided herein is Compound 1 for use in such methodstreating HCC characterized by HBV infection, wherein the methodscomprise administering an effective amount of Compound 1 to a patienthaving HCC characterized by HBV infection, wherein the treatment resultsin a reduction in target lesion size, a reduction in non-target lesionsize, a reduction in target lesion number, a reduction in non-targetlesion number, and/or the absence of all target and/or non-targetlesions, compared to pre-treatment.

In certain embodiments, provided herein are methods for treating HCCcharacterized by HBV infection, the methods comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection, wherein the treatment results in prevention or retardingof clinical progression, such as HCC-related cachexia or increased pain.Provided herein is Compound 1 for use in such methods for treating HCCcharacterized by HBV infection, wherein the methods compriseadministering an effective amount of Compound 1 to a patient having HCCcharacterized by HBV infection, wherein the treatment results inprevention or retarding of clinical progression, such as HCC-relatedcachexia or increased pain.

In one embodiment, provided herein are methods for improving the EasternCooperative Oncology Group Performance Status (ECOG) of a patient havingHCC characterized by HBV infection, comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection. Provided herein is Compound 1 for use in such methods forimproving the Eastern Cooperative Oncology Group Performance Status(ECOG) of a patient having HCC characterized by HBV infection.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed by Positron Emission Tomography (PET)outcome of a patient having HCC characterized by HBV infection,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such methods for inducing a therapeutic responseassessed by Positron Emission Tomography (PET) outcome of a patienthaving HCC characterized by HBV infection. In certain embodiments,provided herein are methods for treating HCC characterized by HBVinfection, the methods comprising administering an effective amount ofCompound 1 to a patient having HCC characterized by HBV infection,wherein the treatment results in a reduction in tumor metabolicactivity, for example, as measured by fluorodeoxyglucose (FDG)-PETimaging. Provided herein is Compound 1 for use in such methods fortreating HCC characterized by HBV infection, wherein the methodscomprises administering an effective amount of Compound 1 to a patienthaving HCC characterized by HBV infection, wherein the treatment resultsin a reduction in tumor metabolic activity, for example, as measured byfluorodeoxyglucose (FDG)-PET imaging. Other molecular imaging agents forPET, such as choline, fluorocholine (FCH), or fluorothylcholine (FEC),are also contemplated.

In yet another embodiment, provided herein are methods for inducing atherapeutic response assessed by angiography outcome of a patient havingHCC characterized by HBV infection, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such methodsfor inducing a therapeutic response assessed by angiography outcome of apatient having HCC characterized by HBV infection. In certainembodiments, provided herein are methods for treating HCC characterizedby HBV infection, the methods comprising administering an effectiveamount of Compound 1 to a patient having HCC characterized by HBVinfection, wherein the treatment results in a reduction in tumor vesselsas assessed by angiography. Provided herein is Compound 1 for use insuch methods for treating HCC characterized by HBV infection, whereinthe methods comprise administering an effective amount of Compound 1 toa patient having HCC characterized by HBV infection, wherein thetreatment results in a reduction in tumor vessels as assessed byangiography.

In still another embodiment, provided herein are methods for inducing atherapeutic response assessed by ultrasonography outcome of a patienthaving HCC characterized by HBV infection, comprising administering aneffective amount of Compound 1 to the patient having HCC characterizedby HBV infection. Provided herein is Compound 1 for use in such methodsfor inducing a therapeutic response assessed by ultrasonography outcomeof a patient having HCC characterized by HBV infection. In certainembodiments, provided herein are methods for treating HCC characterizedby HBV infection, the methods comprising administering an effectiveamount of Compound 1 to a patient having HCC characterized by HBVinfection, wherein the treatment results in a reduction in tumor mass asassessed by ultrasonography. Provided herein is Compound 1 for use insuch methods for treating HCC characterized by HBV infection, themethods comprising administering an effective amount of Compound 1 to apatient having HCC characterized by HBV infection, wherein the treatmentresults in a reduction in tumor mass as assessed by ultrasonography.

In another embodiment, provided herein are methods for inducing atherapeutic response assessed by diffusion-weighted MRI outcome of apatient having HCC characterized by HBV infection, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection. Provided herein is Compound 1 foruse in such methods for inducing a therapeutic response assessed bydiffusion-weighted MRI outcome of a patient having HCC characterized byHBV infection. In certain embodiments, provided herein are methods fortreating HCC characterized by HBV infection, the methods comprisingadministering an effective amount of Compound 1 to a patient having HCCcharacterized by HBV infection, wherein the treatment results in areduction in tumor lesions as assessed by diffusion-weighted MRI.Provided herein is Compound 1 for use in such methods for treating HCCcharacterized by HBV infection, wherein the methods compriseadministering an effective amount of Compound 1 to a patient having HCCcharacterized by HBV infection, wherein the treatment results in areduction in tumor lesions as assessed by diffusion-weighted MRI.

In yet another embodiment, provided herein are methods for inducing atherapeutic response assessed by acoustic radiation force impulse (ARFI)imaging outcome of a patient having HCC characterized by HBV infection,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such methods for inducing a therapeutic responseassessed by acoustic radiation force impulse (ARFI) imaging outcome of apatient having HCC characterized by HBV infection. In certainembodiments, provided herein are methods for treating HCC characterizedby HBV infection, the methods comprising administering an effectiveamount of Compound 1 to a patient having HCC characterized by HBVinfection, wherein the treatment results in a reduction in tumorstiffness as assessed by ARFI imaging. Provided herein is Compound 1 foruse in such methods for treating HCC characterized by HBV infection,wherein the methods comprise administering an effective amount ofCompound 1 to a patient having HCC characterized by HBV infection,wherein the treatment results in a reduction in tumor stiffness asassessed by ARFI imaging.

In certain embodiments, provided herein are methods for treating HCCcharacterized by HBV infection, the methods comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection, wherein the treatment results in a reduction in level ofAFP. Provided herein is Compound 1 for use in such methods for treatingHCC characterized by HBV infection, the methods comprising administeringan effective amount of Compound 1 to a patient having HCC characterizedby HBV infection, wherein the treatment results in a reduction in levelof AFP. In some embodiments, provided herein are methods for reducinglevel of AFP in a patient having HCC characterized by HBV infection,comprising administering an effective amount of Compound 1 to thepatient having HCC characterized by HBV infection. Provided herein isCompound 1 for use in such methods for reducing level of AFP in apatient having HCC characterized by HBV infection. In some suchembodiments, the level of AFP is assessed in a biological sample of thepatient, such as in circulating blood cells and/or tumor biopsies. Insuch embodiments, the level of AFP is assessed by comparison of thelevel of AFP before and after administration of Compound 1. In certainembodiments, provided herein are methods for measuring reduction of AFPlevel in a patient having HCC characterized by HBV infection, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection, measuring the level of AFP in thepatient, and comparing the level of AFP after and before administrationof Compound 1. Provided herein is Compound 1 for use in such methods formeasuring reduction of AFP level in a patient having HCC characterizedby HBV infection, comprising administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection,measuring the level of AFP in the patient, and comparing the level ofAFP after and before administration of Compound 1. In some embodiments,the reduction of AFP level is assessed in circulating blood cells. Insome embodiments, the reduction of AFP level is assessed in tumorbiopsies. In certain embodiments, the AFP level is the mRNA level ofAFP. In other embodiments, the AFP level is the protein level of AFP.

In one embodiment, provided herein are methods for inhibitingphosphorylation of S6RP, 4E-BP1 and/or AKT in a patient having HCCcharacterized by HBV infection, comprising administering an effectiveamount of Compound 1 to the patient having HCC characterized by HBVinfection. Provided herein is Compound 1 for use in such methods forinhibiting phosphorylation of S6RP, 4E-BP1 and/or AKT in a patienthaving HCC characterized by HBV infection. In some such embodiments, theinhibition of phosphorylation is assessed in a biological sample of thepatient, such as in circulating blood cells and/or tumor biopsies. Insuch embodiments, the amount of inhibition of phosphorylation isassessed by comparison of the amount of phospho-S6RP, 4E-BP1 and/or AKTbefore and after administration of Compound 1. In certain embodiments,provided herein are methods for measuring inhibition of phosphorylationof S6RP, 4E-BP1 or AKT in a patient having HCC characterized by HBVinfection, comprising administering an effective amount of Compound 1 tothe patient having HCC characterized by HBV infection, measuring theamount of phosphorylated S6RP, 4E-BP1 and/or AKT in the patient, andcomparing the amount of phosphorylated S6RP, 4E-BP1 and/or AKT after andbefore administration of Compound 1. Provided herein is Compound 1 foruse in such methods for measuring inhibition of phosphorylation of S6RP,4E-BP1 or AKT in a patient having HCC characterized by HBV infection,wherein the method comprises administering an effective amount ofCompound 1 to the patient having HCC characterized by HBV infection,measuring the amount of phosphorylated S6RP, 4E-BP1 and/or AKT in thepatient, and comparing the amount of phosphorylated S6RP, 4E-BP1 and/orAKT after and before administration of Compound 1. In some embodiments,the inhibition of phosphorylation of S6RP, 4E-BP1 and/or AKT is assessedin circulating blood cells. In some embodiments, the inhibition ofphosphorylation of S6RP, 4E-BP1 and/or AKT is assessed in tumorbiopsies.

In certain embodiments, provided herein are methods for inhibitingphosphorylation of S6RP, 4E-BP1 and/or AKT in a biological sample of apatient having HCC characterized by HBV infection, comprisingadministering an effective amount of Compound 1 to the patient havingHCC characterized by HBV infection and comparing the amount ofphosphorylated S6RP, 4E-BP1 and/or AKT in a biological sample of thepatient obtained prior to and after administration of Compound 1,wherein less phosphorylated S6RP, 4E-BP1 and/or AKT in the biologicalsample obtained after administration of Compound 1 relative to theamount of phosphorylated S6RP, 4E-BP1 and/or AKT in the biologicalsample obtained prior to administration of Compound 1 indicatesinhibition. Provided herein is Compound 1 for use in such methods forinhibiting phosphorylation of S6RP, 4E-BP1 and/or AKT in a biologicalsample of a patient having HCC characterized by HBV infection, whereinthe method comprises administering an effective amount of Compound 1 tothe patient having HCC characterized by HBV infection and comparing theamount of phosphorylated S6RP, 4E-BP1 and/or AKT in a biological sampleof the patient obtained prior to and after administration of Compound 1,wherein less phosphorylated S6RP, 4E-BP1 and/or AKT in the biologicalsample obtained after administration of Compound 1 relative to theamount of phosphorylated S6RP, 4E-BP1 and/or AKT in the biologicalsample obtained prior to administration of Compound 1 indicatesinhibition. In some embodiments, the inhibition of phosphorylation ofS6RP, 4E-BP1 and/or AKT is assessed in circulating blood cells. In someembodiments, the inhibition of phosphorylation of S6RP, 4E-BP1 and/orAKT is assessed in tumor biopsies. Inhibition of phosphorylation of S6RP(Ser235/236 and/or Ser240/244), 4E-BP1 (Thr37/46), and/or AKT (Ser473)can be measured by various methodology including flow cytometry, ELISA,immunohistochemistry (IHC), immunofluorescence (IF) usingphosphorylation-specific antibodies.

In some embodiments, provided herein are methods for treating HCCcharacterized by HBV infection, the methods comprising administering aneffective amount of Compound 1 to a patient having HCC characterized byHBV infection, wherein the treatment results in one or more ofinhibition of disease progression, inhibition of tumor growth, reductionof primary tumor, relief of tumor-related symptoms, inhibition of tumorsecreted factors (e.g., AFP), delayed appearance of primary or secondarytumors, slowed development of primary or secondary tumors, decreasedoccurrence of primary or secondary tumors, slowed or decreased severityof secondary effects of disease, arrested tumor growth and regression oftumors, increased TTP, increased PFS, and/or increased OS, among others.Provided herein is Compound 1 for use in such methods for treating HCCcharacterized by HBV infection, wherein the methods compriseadministering an effective amount of Compound 1 to a patient having HCCcharacterized by HBV infection, wherein the treatment results in one ormore of inhibition of disease progression, inhibition of tumor growth,reduction of primary tumor, relief of tumor-related symptoms, inhibitionof tumor secreted factors (e.g., AFP), delayed appearance of primary orsecondary tumors, slowed development of primary or secondary tumors,decreased occurrence of primary or secondary tumors, slowed or decreasedseverity of secondary effects of disease, arrested tumor growth andregression of tumors, increased TTP, increased PFS, and/or increased OS,among others.

Further provided herein are methods for treating patients who have beenpreviously treated for HCC, as well as those who have not previouslybeen treated. Provided herein is Compound 1 for use in such methods fortreating patients who have been previously treated for HCC, as well asthose who have not previously been treated. Further provided herein aremethods for treating patients who have undergone surgery in an attemptto treat HCC, as well as those who have not. Provided herein is Compound1 for use in such methods for treating patients who have undergonesurgery in an attempt to treat HCC, as well as those who have not.Because patients with HCC have heterogeneous clinical manifestations andvarying clinical outcomes, the treatment given to a patient may vary,depending on his/her prognosis. The skilled clinician will be able toreadily determine without undue experimentation specific secondaryagents (see for example U.S. Provisional Application Nos. 61/980,124 and61/980,125 and U.S. Patent Publication Nos. 2015/0297590 and2015/0297605, each incorporated by reference herein in their entirety),types of surgery, and types of non-drug based standard therapy that canbe effectively used to treat an individual patient with HCC.

Compound 1 can be combined with radiation therapy, chemoembolization,radio frequency ablation, thermal techniques (e.g., microwave ablation,laser ablation, and cryoablation), non-thermal techniques (e.g.,reversible electroporation, irreversible electroporation, andlight-activated drug therapy), or surgery. In certain embodiments,Compound 1 is administered to patient who is undergoing radiationtherapy, has previously undergone radiation therapy or will beundergoing radiation therapy. In some embodiments, Compound 1 isadministered to patient who is undergoing chemoembolization, haspreviously undergone chemoembolization or will be undergoingchemoembolization. In other embodiments, Compound 1 is administered topatient who is undergoing radio frequency ablation, has previouslyundergone radio frequency ablation or will be undergoing radio frequencyablation. In yet other embodiments, Compound 1 is administered topatient who is undergoing microwave ablation, has previously undergonemicrowave ablation or will be undergoing microwave ablation. In stillother embodiments, Compound 1 is administered to patient who isundergoing laser ablation, has previously undergone laser ablation orwill be undergoing laser ablation. In certain embodiments, Compound 1 isadministered to patient who is undergoing cryoablation, has previouslyundergone cryoablation or will be undergoing cryoablation. In someembodiments, Compound 1 is administered to patient who is undergoingreversible electroporation, has previously undergone reversibleelectroporation or will be undergoing reversible electroporation. Inother embodiments, Compound 1 is administered to patient who isundergoing irreversible electroporation, has previously undergoneirreversible electroporation or will be undergoing irreversibleelectroporation. In yet other embodiments, Compound 1 is administered topatient who is undergoing light-activated drug therapy, has previouslyundergone light-activated drug therapy or will be undergoinglight-activated drug therapy. In yet other embodiments, Compound 1 isadministered to a patient who is undergoing tumor removal surgery, haspreviously undergone tumor removal surgery or will be undergoing tumorremoval surgery.

Further provided herein are methods of reducing, treating and/orpreventing adverse or undesired effects associated with conventionaltherapy including, but not limited to, surgery, chemotherapy, radiationtherapy, hormonal therapy, biological therapy and immunotherapy.Provided herein is Compound 1 for use in such methods of reducing,treating and/or preventing adverse or undesired effects associated withconventional therapy including, but not limited to, surgery,chemotherapy, radiation therapy, hormonal therapy, biological therapyand immunotherapy. Compound 1 and other active ingredients can beadministered to a patient prior to, during, or after the occurrence ofthe adverse effect associated with conventional therapy.

In some embodiments, the HCC is unresectable HCC. In certainembodiments, the HCC is resistant to at least one anticancer therapy. Inother embodiments, the HCC is relapsed or refractory to at least oneanticancer therapy. In yet other embodiments, the HCC is metastatic.

In each of the embodiments provided herein, the term “HCC characterizedby HBV infection” is interchangeable with the terms “HCC associated withHBV infection,” “HCC related to HBV infection,” “HCC with a history ofHBV infection,” “HBV positive HCC,” “HBV associated HCC,” “HBV relatedHCC,” or “HBV infected HCC.”

5.4 Pharmaceutical Compositions and Routes of Administration

Compositions as provided herein can be used in all methods providedherein.

Provided herein are compositions comprising an effective amount ofCompound 1 and compositions comprising an effective amount of Compound 1and pharmaceutically acceptable carriers or vehicles. In someembodiments, the pharmaceutical composition described herein is suitablefor oral, parenteral, mucosal, transdermal or topical administration.

Compositions of Compound 1 include the pharmaceutical compositionsprovided in U.S. Pat. No. 9,403,829, issued on Aug. 2, 2016; and U.S.Pat. No. 9,604,939, issued on Mar. 28, 2017, the entire contents of eachof which are incorporated herein by reference.

Compound 1 can be administered to a patient orally or parenterally inthe conventional form of preparations, such as capsules, microcapsules,tablets, granules, powder, troches, pills, suppositories, injections,suspensions and syrups. Suitable formulations can be prepared by methodscommonly employed using conventional, organic or inorganic additives,such as an excipient (e.g., sucrose, starch, mannitol, sorbitol,lactose, glucose, cellulose, talc, calcium phosphate or calciumcarbonate), a binder (e.g., cellulose, methylcellulose,hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone,gelatin, gum arabic, polyethyleneglycol, sucrose or starch), adisintegrator (e.g., starch, carboxymethylcellulose,hydroxypropylstarch, low substituted hydroxypropylcellulose, sodiumbicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g.,magnesium stearate, light anhydrous silicic acid, talc or sodium laurylsulfate), a flavoring agent (e.g., citric acid, menthol, glycine ororange powder), a preservative (e.g, sodium benzoate, sodium bisulfite,methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodiumcitrate or acetic acid), a suspending agent (e.g., methylcellulose,polyvinyl pyrroliclone or aluminum stearate), a dispersing agent (e.g.,hydroxypropylmethylcellulose), a diluent (e.g., water), and base wax(e.g., cocoa butter, white petrolatum or polyethylene glycol). Theeffective amount of Compound 1 in the pharmaceutical composition may beat a level that will exercise the desired effect; for example, about0.005 mg/kg of a patient's body weight to about 10 mg/kg of a patient'sbody weight in unit dosage for both oral and parenteral administration.In certain embodiments, the pharmaceutical composition comprisesCompound 1 and suitable additives. In other embodiments, thepharmaceutical composition comprises Compound 1 only. In yet otherembodiments, the pharmaceutical composition comprises Compound 1 andsuitable additives in capsules. In still other embodiments, thepharmaceutical composition comprises Compound 1 only in capsules.

The dose of Compound 1 to be administered to a patient is rather widelyvariable and can be patient-dependent to the judgment of a health-carepractitioner. In general, Compound 1 can be administered one to fourtimes a day in a dose of about 0.005 mg/kg of a patient's body weight toabout 10 mg/kg of a patient's body weight in a patient, but the abovedosage may be properly varied depending on the age, body weight andmedical condition of the patient and the type of administration. In oneembodiment, the dose is about 0.01 mg/kg of a patient's body weight toabout 5 mg/kg of a patient's body weight, about 0.05 mg/kg of apatient's body weight to about 1 mg/kg of a patient's body weight, about0.1 mg/kg of a patient's body weight to about 0.75 mg/kg of a patient'sbody weight or about 0.25 mg/kg of a patient's body weight to about 0.5mg/kg of a patient's body weight. In one embodiment, one dose is givenper day. In another embodiment, two doses are given per day. In anygiven case, the amount of Compound 1 administered will depend on suchfactors as the solubility of the active component, the formulation usedand the route of administration. In some embodiments, the effectiveamount of Compound 1 in the pharmaceutical composition is about 0.01,0.25, 0.05, 0.75, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0,3.0, 4.0, 5.0 mg/kg of a patient's body weight in unit dosage for oraladministration. In one embodiment, the effective amount of Compound 1 inthe pharmaceutical composition is about 0.21 mg/kg of a patient's bodyweight in unit dosage for oral administration. In another embodiment,the effective amount of Compound 1 in the pharmaceutical composition isabout 0.43 mg/kg of a patient's body weight in unit dosage for oraladministration. In yet another embodiment, the effective amount ofCompound 1 in the pharmaceutical composition is about 0.64 mg/kg of apatient's body weight in unit dosage for oral administration.

In another embodiment, provided herein are methods for the treatment orprevention of HCC characterized by HBV infection comprisingadministration of about 0.375 mg/day to about 750 mg/day, about 0.75mg/day to about 375 mg/day, about 3.75 mg/day to about 75 mg/day, about7.5 mg/day to about 55 mg/day or about 18 mg/day to about 37 mg/day ofCompound 1 to a patient in need thereof. Provided herein is Compound 1for use in such methods for the treatment or prevention of HCCcharacterized by HBV infection, wherein the method comprisesadministration of about 0.375 mg/day to about 750 mg/day, about 0.75mg/day to about 375 mg/day, about 3.75 mg/day to about 75 mg/day, about7.5 mg/day to about 55 mg/day or about 18 mg/day to about 37 mg/day ofCompound 1 to a patient in need thereof. In a particular embodiment, themethods disclosed herein comprise administration of 15 mg/day, 30mg/day, 45 mg/day or 60 mg/day of Compound 1 to a patient in needthereof. In another embodiment, the methods disclosed herein compriseadministration of 0.5 mg/day, 1 mg/day, 2 mg/day, 4 mg/day, 8 mg/day, 16mg/day, 20 mg/day, 25 mg/day, 30 mg/day or 40 mg/day of Compound 1 to apatient in need thereof. In a particular embodiment, the methodsdisclosed herein comprise administration of 15 mg/day, 20 mg/day, or 30mg/day of Compound 1 to a patient in need thereof. In some suchembodiments, the methods additionally comprise administration of 240 mgnivolumab every 2 weeks. In some such embodiments, the methodsadditionally comprise administration of 480 mg nivolumab every 4 weeks.

In another embodiment, provided herein are methods for the treatment orprevention of HCC characterized by HBV infection comprisingadministration of about 0.1 mg/day to about 1200 mg/day, about 1 mg/dayto about 100 mg/day, about 10 mg/day to about 1200 mg/day, about 10mg/day to about 100 mg/day, about 100 mg/day to about 1200 mg/day, about400 mg/day to about 1200 mg/day, about 600 mg/day to about 1200 mg/day,about 400 mg/day to about 800 mg/day or about 600 mg/day to about 800mg/day of Compound 1 to a patient in need thereof. Provided herein isCompound 1 for use in such methods for the treatment or prevention ofHCC characterized by HBV infection, wherein the method comprisesadministration of about 0.1 mg/day to about 1200 mg/day, about 1 mg/dayto about 100 mg/day, about 10 mg/day to about 1200 mg/day, about 10mg/day to about 100 mg/day, about 100 mg/day to about 1200 mg/day, about400 mg/day to about 1200 mg/day, about 600 mg/day to about 1200 mg/day,about 400 mg/day to about 800 mg/day or about 600 mg/day to about 800mg/day of Compound 1 to a patient in need thereof. In a particularembodiment, the methods disclosed herein comprise administration of 0.1mg/day, 0.5 mg/day, 1 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, 30mg/day, 40 mg/day, 45 mg/day, 50 mg/day, 60 mg/day, 75 mg/day, 100mg/day, 125 mg/day, 150 mg/day, 200 mg/day, 250 mg/day, 300 mg/day, 400mg/day, 600 mg/day or 800 mg/day of Compound 1 to a patient in needthereof. In a specific embodiment, the methods disclosed herein compriseadministration of 0.1 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 0.5 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 1 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 10 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 15 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 20 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, provided herein are methods for the treatmentor prevention of HCC characterized by HBV infection comprisingadministration of 30 mg/day of Compound 1 to a patient in need thereof.Provided herein is Compound 1 for use in such methods for the treatmentor prevention of HCC characterized by HBV infection, wherein the methodcomprises administration of 30 mg/day of Compound 1 to a patient in needthereof. In a specific embodiment, the methods disclosed herein compriseadministration of 40 mg/day of Compound 1 to a patient in need thereof.In another specific embodiment, provided herein are methods for thetreatment or prevention of HCC characterized by HBV infection comprisingadministration of 45 mg/day of Compound 1 to a patient in need thereof.Provided herein is Compound 1 for use in such methods for the treatmentor prevention of HCC characterized by HBV infection, wherein the methodcomprises administration of 45 mg/day of Compound 1 to a patient in needthereof. In a specific embodiment, the methods disclosed herein compriseadministration of 50 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 60 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 75 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 100 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 125 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 150 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 200 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 250 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 300 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 400 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 600 mg/day of Compound 1 to a patient in need thereof.In a specific embodiment, the methods disclosed herein compriseadministration of 800 mg/day of Compound 1 to a patient in need thereof.In some such embodiments, the methods additionally compriseadministration of 240 mg nivolumab every 2 weeks. In some suchembodiments, the methods additionally comprise administration of 480 mgnivolumab every 4 weeks.

In another embodiment, provided herein are unit dosage formulations thatcomprise between about 0.1 mg and about 2000 mg, about 1 mg and 200 mg,about 35 mg and about 1400 mg, about 125 mg and about 1000 mg, about 250mg and about 1000 mg, or about 500 mg and about 1000 mg of Compound 1.In one embodiment, provided herein are unit dosage formulations thatcomprise between about 0.1 mg and about 2000 mg of Compound 1. In oneembodiment, provided herein are unit dosage formulations that comprisebetween about 1 mg and 200 mg of Compound 1. In one embodiment, providedherein are unit dosage formulations that comprise between about 35 mgand about 1400 mg of Compound 1. In one embodiment, provided herein areunit dosage formulations that comprise between about 125 mg and about1000 mg of Compound 1. In one embodiment, provided herein are unitdosage formulations that comprise between about 250 mg and about 1000 mgof Compound 1. In one embodiment, provided herein are unit dosageformulations that comprise between about 500 mg and about 1000 mg ofCompound 1.

In a particular embodiment, provided herein are unit dosage formulationcomprising about 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20mg, 30 mg, 45 mg, 50 mg, 60 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg,250 mg, 300 mg, 400 mg, 600 mg or 800 mg of Compound 1.

In another embodiment, provided herein are unit dosage formulations thatcomprise 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg,250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg or 1400mg of Compound 1. In a particular embodiment, provided herein are unitdosage formulations that comprise about 5 mg, about 15 mg, about 20 mg,about 30 mg, about 45 mg, and about 50 mg of Compound 1. In oneembodiment, provided herein are unit dosage formulations that comprise0.1 mg of Compound 1. In one embodiment, provided herein are unit dosageformulations that comprise 0.25 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 0.5 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 1 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 2.5 mg ofCompound 1. In another embodiment, provided herein are unit dosageformulations that comprise 5 mg of Compound 1. In yet anotherembodiment, provided herein are unit dosage formulations that comprise10 mg of Compound 1. In one embodiment, provided herein are unit dosageformulations that comprise 15 mg of Compound 1. In still anotherembodiment, provided herein are unit dosage formulations that comprise20 mg of Compound 1. In one embodiment, provided herein are unit dosageformulations that comprise 30 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 35 mg ofCompound 1. In another embodiment, provided herein are unit dosageformulations that comprise 45 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 50 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 60 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 70 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 100 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 125 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 140 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 175 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 200 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 250 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 280 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 350 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 500 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 560 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 700 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 750 mg ofCompound 1. In one embodiment, provided herein are unit dosageformulations that comprise 1000 mg of Compound 1. In one embodiment,provided herein are unit dosage formulations that comprise 1400 mg ofCompound 1.

Compound 1 can be administered once daily (QD), or divided into multipledaily doses such as twice daily (BID), three times daily (TID), and fourtimes daily (QID). In a specific embodiment, Compound 1 is administeredQD. In another embodiment, Compound 1 is administered BID. In yetanother embodiment, Compound 1 is administered TID. In still anotherembodiment, Compound 1 is administered QID. In addition, theadministration can be continuous (i.e., daily for consecutive days orevery day), intermittent, e.g., in cycles (i.e., including days, weeks,or months of rest without drug). In a preferred embodiment, theadministration is continuous. In another preferred embodiment, Compound1 is administered in 28-day cycles. In a preferred embodiment, Compound1 is administered continuously in a daily dosing in 28-day cycles. In apreferred embodiment, Compound 1 is administered continuously in a dailydosing in 28-day cycles at a dose of 30 mg/day. In a preferredembodiment, Compound 1 is administered continuously in a daily dosing in28-day cycles at a dose of 45 mg/day. In a preferred embodiment,Compound 1 is administered continuously in a daily dosing in 28-daycycles at a dose of 30 mg/day with no rest period between each 28-daycycle. In a preferred embodiment, Compound 1 is administeredcontinuously in a daily dosing in 28-day cycles at a dose of 45 mg/daywith no rest period between each 28-day cycle.

Compound 1 can be administered orally for reasons of convenience. In oneembodiment, when administered orally, Compound 1 is administered with ameal and water. In another embodiment, Compound 1 is dispersed in wateror juice (e.g., apple juice or orange juice) and administered orally asa suspension. In another embodiment, when administered orally, Compound1 is administered in a fasted state. Preferably, Compound 1 isadministered orally. In one preferred embodiment, Compound 1 isadministered orally at a dose of 30 mg/day. In another preferredembodiment, Compound 1 is administered orally at a dose of 45 mg/day. Ina preferred embodiment, Compound 1 is administered continuously in adaily oral dosing in 28-day cycles at a dose of 30 mg/day. In anotherpreferred embodiment, Compound 1 is administered continuously in a dailyoral dosing in 28-day cycles at a dose of 45 mg/day. In a preferredembodiment, Compound 1 is administered continuously in a daily oraldosing in 28-day cycles at a dose of 30 mg/day with no rest periodbetween each 28-day cycle. In another preferred embodiment, Compound 1is administered continuously in a daily oral dosing in 28-day cycles ata dose of 45 mg/day with no rest period between each 28-day cycle.

Compound 1 can also be administered intradermally, intramuscularly,intraperitoneally, percutaneously, intravenously, subcutaneously,intranasally, epidurally, sublingually, intracerebrally, intravaginally,transdermally, rectally, mucosally, by inhalation, or topically to theears, nose, eyes, or skin. The mode of administration is left to thediscretion of the health-care practitioner and can depend in-part uponthe site of the medical condition.

In one embodiment, provided herein are capsules containing Compound 1without an additional carrier, excipient or vehicle.

In another embodiment, provided herein are compositions comprising aneffective amount of Compound 1 and a pharmaceutically acceptable carrieror vehicle, wherein a pharmaceutically acceptable carrier or vehicle cancomprise an excipient, diluent, or a mixture thereof. In one embodiment,the composition is a pharmaceutical composition.

The compositions can be in the form of tablets, chewable tablets,capsules, solutions, parenteral solutions, troches, suppositories andsuspensions and the like. Compositions can be formulated to contain adaily dose, or a convenient fraction of a daily dose, in a dosage unit,which may be a single tablet or capsule or convenient volume of aliquid. In one embodiment, the solutions are prepared from water-solublesalts, such as the hydrochloride salt. In general, all of thecompositions are prepared according to known methods in pharmaceuticalchemistry. Capsules can be prepared by mixing Compound 1 with a suitablecarrier or diluent and filling the proper amount of the mixture incapsules. The usual carriers and diluents include, but are not limitedto, inert powdered substances such as starch of many different kinds,powdered cellulose, especially crystalline and microcrystallinecellulose, sugars such as fructose, mannitol and sucrose, grain floursand similar edible powders.

Tablets can be prepared by direct compression, by wet granulation, or bydry granulation. Their formulations usually incorporate diluents,binders, lubricants and disintegrators as well as the compound. Typicaldiluents include, for example, various types of starch, lactose,mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such assodium chloride and powdered sugar. Powdered cellulose derivatives arealso useful. In one embodiment, the pharmaceutical composition islactose-free. Typical tablet binders are substances such as starch,gelatin and sugars such as lactose, fructose, glucose and the like.Natural and synthetic gums are also convenient, including acacia,alginates, methylcellulose, polyvinylpyrrolidine and the like.Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

A lubricant might be necessary in a tablet formulation to prevent thetablet and punches from sticking in the die. The lubricant can be chosenfrom such slippery solids as talc, magnesium and calcium stearate,stearic acid and hydrogenated vegetable oils. Tablet disintegrators aresubstances that swell when wetted to break up the tablet and release thecompound. They include starches, clays, celluloses, algins and gums.More particularly, corn and potato starches, methylcellulose, agar,bentonite, wood cellulose, powdered natural sponge, cation-exchangeresins, alginic acid, guar gum, citrus pulp and carboxymethyl cellulose,for example, can be used as well as sodium lauryl sulfate. Tablets canbe coated with sugar as a flavor and sealant, or with film-formingprotecting agents to modify the dissolution properties of the tablet.The compositions can also be formulated as chewable tablets, forexample, by using substances such as mannitol in the formulation.

When it is desired to administer Compound 1 as a suppository, typicalbases can be used. Cocoa butter is a traditional suppository base, whichcan be modified by addition of waxes to raise its melting pointslightly. Water-miscible suppository bases comprising, particularly,polyethylene glycols of various molecular weights are in wide use.

The effect of Compound 1 can be delayed or prolonged by properformulation. For example, a slowly soluble pellet of Compound 1 can beprepared and incorporated in a tablet or capsule, or as a slow-releaseimplantable device. The technique also includes making pellets ofseveral different dissolution rates and filling capsules with a mixtureof the pellets. Tablets or capsules can be coated with a film thatresists dissolution for a predictable period of time. Even theparenteral preparations can be made long-acting, by dissolving orsuspending Compound 1 in oily or emulsified vehicles that allow it todisperse slowly in the serum.

5.5 Kits

In certain embodiments, provided herein are kits comprising Compound 1.In particular embodiments, provided herein are kits comprising a unitdosage form comprising Compound 1 in a sealed container, wherein theunit dosage form comprises about 1 mg to about 100 mg of Compound 1. Inparticular embodiments, provided herein are kits comprising a unitdosage form comprising Compound 1 in a sealed container, wherein theunit dosage form comprises about 5 mg, about 20 mg or about 50 mg ofCompound 1.

In other embodiments, provide herein are kits comprising Compound 1 andmeans for monitoring patient response to administration of Compound 1.In certain embodiments, the patient has HCC characterized by HBVinfection. In particular embodiments, the patient response measured isinhibition of disease progression, inhibition of tumor growth, reductionof primary and/or secondary tumor(s), relief of tumor-related symptoms,improvement in quality of life, inhibition of tumor secreted factors(e.g., AFP), delayed appearance of primary and/or secondary tumor(s),slowed development of primary and/or secondary tumor(s), decreasedoccurrence of primary and/or secondary tumor(s), slowed or decreasedseverity of secondary effects of disease, arrested tumor growth and/orregression of tumors.

In other embodiments, provide herein are kits comprising Compound 1 andmeans for monitoring patient response to administration of Compound 1,wherein said response is RECIST (for example, RECIST 1.1 or mRECIST forHCC) or ECOG.

In other embodiments, provided herein are kits comprising Compound 1 andmeans for measuring the amount of inhibition of phosphorylation of S6RP,4E-BP1 and/or AKT in a patient. In certain embodiments, the kitscomprise means for measuring inhibition of phosphorylation of S6RP,4E-BP1 and/or AKT in circulating blood cells and/or tumor biopsies of apatient. In certain embodiments, provided herein are kits comprisingCompound 1 and means for measuring the amount of inhibition ofphosphorylation as assessed by comparison of the amount of phospho-S6RP,4E-BP1 and/or AKT before, during and/or after administration ofCompound 1. In certain embodiments, the patient has HCC characterized byHBV infection.

Inhibition of phosphorylation of S6RP, 4E-BP1, and/or AKT can bemeasured in blood, skin, tumor, and/or circulating tumor cells (CTCs) inblood by various methodology including flow cytometry, ELISA, IHC usingphosphorylation-specific antibodies.

In certain embodiments, the kits provided herein comprise an amount ofCompound 1 effective for treating or preventing HCC characterized by HBVinfection.

In certain embodiments, the kits provided herein further compriseinstructions for use, such as for administering Compound 1 and/ormonitoring patient response to administration of Compound 1.

6. EXAMPLES 6.1 Clinical Study 1

A Phase 1/2 Multi-Center, Open-Label, Dose Finding Study to Assess theSafety, Tolerability, PK and Preliminary Efficacy of Compound 1Administered Orally to Subjects with Phase 1/2, Multi-Center,Open-Label, Dose Finding Study to Assess the Safety, Tolerability, PKand Preliminary Efficacy of Compound 1 Administered Orally to Subjectswith Phase 1/2, Multi-Center, Open Label, Dose Finding Study to Assessthe Safety, Tolerability, PK and Preliminary Efficacy of Compound 1Administered Orally to Subjects with Phase 1/2, Multi-Center,Open-Label, Dose Finding Study to Assess the Safety, Tolerability, PKand Preliminary Efficacy of Compound 1 Administered Orally to Subjectswith HCC.

The study was designed as a Phase 1/2 trial consisting of two parts:dose escalation (Part A) and dose expansion (Part B).

Part A was an open-label, dose-escalating study of subjects with varioushematologic or solid malignancies. The primary objectives were todetermine the maximum tolerated dose (MTD) and the preliminary PK ofCompound 1. The MTD of Compound 1 was determined to be 45 mg/day, andthe nontolerated dose (NTD) was determined to be 60 mg/day. The PK andPD data supported once daily dosing with Compound 1.

Part B, the preliminary efficacy-seeking phase, was an open-label,dose-expansion study, which involved subjects with HCC.

The primary objectives for Part B were (a) to determine the safety andtolerability of Compound 1 when administered orally and (b) to determinethe preliminary PK of Compound 1 following both single and multiple oraldosing of Compound 1.

The secondary objectives of Part B were: (a) to provide information onthe preliminary efficacy of Compound 1; (b) to characterize the PK of M1(the metabolite of Compound 1) following oral dosing of Compound 1; (c)to characterize the PK of Compound 1 and M1 in subjects with HCC; and(d) to evaluate the extent of inhibition of phosphorylation of S6RPand/or 4E-BP1 for mTORC1 activity and AKT and/or other relevantbiomarkers for mTORC2 activity in peripheral blood samples and tumorbiopsies following treatment with Compound 1.

Subjects received continuous daily dosing of Compound 1 in 28-day cycles(FIG. 1). Therapy was discontinued if there was evidence of diseaseprogression, but subjects continued to receive Compound 1 as long as theinvestigator considered that the subjects derived benefit fromtreatment. Therapy was discontinued if there was unacceptable toxicityor if the subject decided to withdraw from the study. Subjects werecontacted 28 days after the last dose of study drug to assess the statusof adverse events (AEs) and to determine whether any new events or deathhad occurred. In addition to those subjects who had died on study,approximately 28 subjects were consented for follow-up every 2 months(±1 week) after completing the treatment phase in order to determinetheir date of death and complete an overall survival analysis.

The inclusion criteria for selection of study population include: (1)understand and voluntarily sign an informed consent document prior toany study-related assessments/procedures were conducted; (2) men andwomen, ≥18 years old, with histologically or cytologically-confirmed,advanced unresectable HCC including subjects who had progressed on (ornot been able to tolerate) standard anticancer therapy or for whom nostandard anticancer therapy exists; (3) ECOG performance status of 0 or1; (4) subjects must have had the following laboratory values: absoluteneutrophil count≥1.5×109/L, hemoglobin≥9 g/dL, platelets≥100×109/L,potassium within normal limits or correctable with supplements,aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤2.5×upper limit of normal (ULN) or ≤5.0×ULN, serum bilirubin≤1.5×ULN or≤2×ULN, serum creatinine≤1.5×ULN or 24-hour clearance≥50 mL/min,negative serum or urine pregnancy test within 48 hours before startingstudy treatment in females of childbearing potential; (5) able to adhereto the study visit schedule and other protocol requirements; (6)retrieval of formalin-fixed, paraffin embedded archival tumor tissue,either in tumor blocks or sectioned/mounted specimens for gene mutationand/or IHC biomarker assay. Only in exceptional circumstances was anexemption waiver granted by the sponsor. (7) satisfactory screeningbiopsy for gene mutation and/or IHC biomarker assay for accessibletumors; (8) histologically-confirmed HCC with measurable disease. Thefollowing criteria are in addition to, or supersede, above criteriawhere applicable: platelet count≥60×109/L if portal hypertension waspresent, Child-Pugh score of <7 (i.e., Class A liver function orbetter), at least 4 weeks from last dose of α-interferon and/orribavirin, at least 4 weeks from prior percutaneous ethanol injection,radiofrequency ablation, transarterial embolization, or cryotherapy withdocumentation of progressive or recurrent disease.

The exclusion criteria for selection of study population include: (1)symptomatic central nervous system metastases. Subjects with brainmetastases that had been previously treated and were stable for 6 weekswere allowed. (2) known acute or chronic pancreatitis; (3) subjects withany peripheral neuropathy≥National Cancer Institute Common TerminologyCriteria for Adverse Events (NCI CTCAE) Grade 2; (4) subjects withpersistent diarrhea or malabsorption Grade≥2, despite medicalmanagement; (5) impaired cardiac function or clinically significantcardiac diseases, including any of the following: left ventricularejection fraction (LVEF)<45% as determined by multiple gated acquisition(MUGA) scan or echocardiogram, complete left bundle branch, orbifascicular, block, congenital long QT syndrome, persistent orclinically meaningful ventricular arrhythmias or atrial fibrillation, QTinterval with Fridericia correction (QTcF)>460 msec on screening ECG(mean of triplicate recordings), unstable angina pectoris or myocardialinfarction≤3 months prior to starting Compound 1, other clinicallysignificant heart disease such as congestive heart failure requiringtreatment or uncontrolled hypertension (blood pressure≥160/95 mmHg); (6)subjects with diabetes on active treatment or subjects with either ofthe following: fasting blood glucose≥126 mg/dL (7.0 mmol/L), orglycosylated hemoglobin (HbAlc)≥6.5%; (7) other concurrent severe and/oruncontrolled concomitant medical conditions (e.g., active oruncontrolled infection) that could have caused unacceptable safety risksor compromised compliance with the protocol; (8) prior systemiccancer-directed treatments or investigational modalities≤5 half lives or4 weeks, whichever was shorter, prior to starting study drug or who hadnot recovered from side effects of such therapy. Subjects must haverecovered from any effects of recent radiotherapy that might haveconfounded the safety evaluation of study drug. (9) subjects who hadundergone major surgery≤2 weeks prior to starting study drug or who hadnot recovered from side effects of such therapy; (10) women who werepregnant or breast feeding. Adults of reproductive potential notemploying 2 forms of birth control: (a) female subjects of childbearingpotential must have agreed to use 2 adequate forms of contraceptionmethods simultaneously (one must have been non-hormonal) from the timeof giving informed consent until 28 days after the last dose ofCompound 1. Female subjects of child-bearing potential, defined assexually mature women who had not undergone a hysterectomy or bilateraloophorectomy, or who had not been naturally postmenopausal (i.e., whohad not menstruated at all) for at least 24 consecutive months. (b) malesubjects with partners who were female with child-bearing potential musthave agreed that they or their partners would use at least 2 effectivecontraceptive methods (including 1 barrier method) when engaging inreproductive sexual activity throughout the study, and would avoidconceiving for 28 days after the last dose of Compound 1. (11) subjectswith known human immunodeficiency virus infection; (12) any significantmedical condition, laboratory abnormality, or psychiatric illness thatwould have prevented the subject from participating in the study; (13)any condition including the presence of laboratory abnormalities, whichplaced the subject at unacceptable risk if he/she were to participate inthe study; (14) any condition that confounded the ability to interpretdata from the study; (15) concurrent active second malignancy for whichthe subject was receiving therapy, excluding nonmelanomatous skin canceror carcinoma in situ of the cervix.

Compound 1 was supplied in three strengths, 2.5 mg, 10 mg, and 20 mg,containing only the active pharmaceutical ingredient in reddish brownsize Number 1 gelatin capsules for oral administration. No otherexcipients were used.

HBV Status of HCC Patients

An algorithm was developed to identify study subjects with HCCconsidered to have either a chronic HBV or a history of it. Variables inthe clinical trial database used for the algorithm included thefollowing: history of HBV, prior or current treatment for HBV, cirrhosisattributed to HBV, and hepatitis serology (Table 1). A review using thealgorithm identified 12 subjects as HBV positive.

TABLE 1 Determination of HBV Status of Subjects Using AlgorithmSerology^(a) Final HBV Anti- Anti- HBV Status HBsAg HBsAg HBcAg HBV loadmedications Determination + Positive >20 IU/mL Positive + + +Positive + + Positive + + Positive + Positive + + + + Positive + + +Positive + + Positive + Negative + Negative Anti-HBc = antibody tohepatitis B core antigen; Anti-HBs = antibody to hepatitis B surfaceantigen; HBsAG = hepatitis B surface antigen; HBV = hepatitis B virus.^(a)“+” = Positive serology for HBsAG, antiHBs, antiHBc, or HBV viralload at screening or Cycle 1 Day 1.

Accordingly to the original protocol of Part B, 25 HCC patients startedtreatment of Compound 1 at 45 mg/day. After the protocol Amendment 9, 28new HCC subjects in an additional cohort were started at 30 mg/day. Theappropriateness of the 30 mg/day dose was supported by the PK and PDdata from Part A. Compound 1 was administered orally, in anuninterrupted once daily schedule with no rest period between each28-day cycle. Subjects continued to receive Compound 1 for as long asthey derived benefit from treatment as judged by the investigator.Patient characteristics of the HCC patients are shown in FIG. 2.

PK Analysis

The PK profiles of Compound 1 and its metabolite M1 were determined fromserial blood and urine collections during the first treatment cycle.Plasma and urine Compound 1 and M1 were measured using validated chiralliquid chromatography-mass spectrometry methods. The lower limit ofquantification (LLOQ) in plasma was 1.00 or 2.00 ng/mL for Compound 1and 10.0 ng/mL for M1. The LLOQ in urine was 5.00 ng/mL for Compound 1and 20 ng/mL for M1.

The following general PK parameters were assessed:

-   -   AUC_(∞): area under the plasma concentration-time curve after a        dose of Compound 1    -   AUC₁: area under the plasma concentration-time curve from time 0        to the last measurable concentration at time t    -   AUC_(t): area under the plasma concentration-time curve from        time 0 to τ, where τ is the dosing interval    -   AUC_(% extrap): percentage of AUC_(∞) due to extrapolation from        the last quantifiable time to infinity    -   C_(max): peak (maximum) plasma concentration    -   T_(max): time to peak (maximum) plasma concentration    -   CL/F: total body clearance    -   CL_(ss)/F: total body clearance at steady state    -   Vz/F: apparent volume of distribution    -   Rac (AUC_(t)): accumulation ratio based on AUC_(t)    -   T_(last): time of last measurable concentration    -   C_(last): last measurable concentration    -   λ_(z): terminal elimination rate constant (first-order)    -   λ_(z) lower: lower limit of time (h) included in the calculation        of λ_(z)    -   λ_(z) N: number of data points used in the calculation of λ_(z)    -   λ_(z) upper: upper limit of time (h) included in the calculation        of λ_(z)    -   HL λ_(z): terminal half-life

FIGS. 3A and 3B show plasma concentration of Compound 1 (FIG. 3A) andits metabolite M1 (FIG. 3B) in HBV infected HCC patients (n=12) andnon-HBV infected HCC patients (n=39). In FIG. 3A, overlap of theexposure data for HBV infected HCC patients and non-HBV infected HCCpatients indicates that the Compound 1 exposure in HBV infected HCCpatients is comparable to the exposure observed in non-HBV infected HCCpatients. Similar results for the M1 exposure were shown in FIG. 3B.

Subject Disposition for the HCC Patients

All subjects enrolled in Part B were included in the analysis of subjectdisposition. Reasons for study discontinuation include the followingcategories: adverse effect, disease progression, withdrew consent,death, lost to follow-up, protocol violation, and other.

Information on HCC patient disposition by HBV status in the TP is shownin FIG. 4. Of the 25 HCC patients enrolled for 45 mg/day Compound 1treatment, 17 were determined to be EE. Of the 28 HCC patients enrolledfor 30 mg/day Compound 1 treatment, 24 were determined to be EE. Thus,of the total 53 HCC patients, 41 patients were evaluable for efficacyafter 13 withdrew prior to first valid restaging. Of the total 53 HCCpatients, 12 were determined to be HBV infected, and 41 were non-HBVinfected.

Efficacy Analysis

All efficacy analyses were based on both the TP and EE Population.Subjects were evaluated for efficacy during Cycles 2, 4, 6, and every 3months after Cycle 6. The primary efficacy variable was response rate.Efficacy endpoints for HCC matured once all enrolled subjects hadwithdrawn from the study.

Tumor response for HCC was based on investigator's overall evaluationwith RECIST. Response rate was determined by a best overall response ofeither CR or PR. Disease control rate (DCR) included CR, PR, and SD.

OS was defined as the time from first dose to death. All deaths,regardless of the cause of death, were included. Subjects who had notdied were censored at the last contact date when the subject was knownto be alive or the clinical cut-off date, whichever was earlier.

Median of OS times were calculated using the Kaplan-Meier method and thecorresponding 95% CIs were presented. The Kaplan-Meier survival curvesare presented in FIGS. 5A and 5B.

Median OS for the HCC cohort was 6.9 months (FIG. 5A), and median PFSwas 16 weeks (FIG. 6A). Although it was not statistically significant, atrend towards increased OS in HBV infected HCC patients versus non-HBVinfected HCC patients was observed. For example, the median OS for HBVinfected HCC patients was 12.07 months, whereas the median OS fornon-HBV infected HCC patients was 5.16 months (p=0.19) (FIGS. 5B and 8).Radiographic responses of target lesions are summarized in a waterfallplot (FIG. 7). Five subjects had >30% regression of target tumor lesionwith best overall responses by RECIST 1.1 of 3 PR, 1 SD and 1 PD. Ofthese 5 subjects, the 3 subjects with PR were HBV positive, the subjectwith SD was HBV negative, and the subject with PD was HBV negative. Inaddition, the disease control rate (DCR) for all subjects was 54.7% (95%CI: 40.4%, 68.4%). By HBV status, the DCR was 91.7% (95% CI: 61.5%,99.8%) for subjects who were HBV positive and 43.9% (95% CI: 28.5%,60.3%) for those who were HBV negative (p=0.0066) (FIG. 8).

The rate of target tumor shrinkage (i.e., lesions reducing in sizerelative to screening) for all subjects was 45.3% (95% CI: 31.6%,59.6%). By HBV status, the target tumor shrinkage rate was 66.7% (95%CI: 34.9, 90.1%) for subjects who were HBV positive was and 39.0% (95%CI: 24.2%, 55.5%) for those who were HBV negative (data not shown).

Illustrative examples of radiographic improvement in two patientstreated with Compound 1 are shown in FIG. 9. Patient A shows regressionof intrathoracic metastases at the first on-treatment restaging comparedto baseline. Patient B shows intrahepatic tumor regression at the firston-treatment restaging compared to baseline.

Assessment of AFP and HBV Viral Load for the HCC Patients

For the HCC subjects, baseline and change from baseline in AFP and HBVviral load (HBsAg positive subjects only) were summarized withdescriptive statistics. In addition, a Wilcoxon's signed rank test wasconducted to analyze change from baseline in AFP at selected scheduledvisits. The p-values of such tests were provided. Change from baselinein HBV viral load was analyzed similarly. The percentage of subjectswith a >50% decline from baseline in AFP was summarized for the TP.

Examples of AFP reduction in two HBV positive patients who were treatedwith Compound 1 and showed PR are shown in FIG. 10. Both patients showearly clinically significant, marked reduction of AFP on treatmentcompared to baseline elevated levels.

Discussion.

For the HCC TP, the overall response rate (ORR) was 5.7%. No subjectexperienced a CR. While modest, the objective response rate iscomparable to that reported for sorafenib, a compound approved for thetreatment of advanced HCC (Llovet et al, N Engl J Med, 2008, 359:78-90).A total of 49.1% of subjects showed a best response of SD, yielding aDCR of 54.7%. Relative to pretreatment, 45.3% of subjects showed targetlesion regression. For the EE Population, also considered an importantsubgroup to evaluate for tumor response in early phase studies, the ORRwas 7.3%, the DCR was 68.3%, and rate of tumor regression relative topretreatment was 56.1%. For the 3 subjects who reached PR, the medianduration of response (DOR) was 124.0 days. For the 26 subjects with abest response of SD, the median duration of SD was 112.0 days. For theTP, median PFS was 3.7 months and median OS was 30.0 weeks; the EEpopulation outcomes were very similar.

Although not always statistically significant, all response outcomeswere numerically more favorable in the subset of HCC subjects who wereHBV positive compared with those with other risk factors (hepatitis Cvirus or non-infectious). All 3 subjects achieving PR were HBV positive,yielding an ORR of 25% compared with 0% in the HBV negative subgroups.The DCR was 91.7% versus 43.9%, the tumor regression rate relative tobaseline was 66.7% versus 39.0%, median PFS was 14.8 versus 14.4 weeks,and median OS was 52.4 versus 22.4 weeks. These differences could not becompletely explained by imbalances for baseline disease characteristicsalthough HBV positive subjects were younger, male, and primarily Asian.

Conclusion.

Treatment with Compound 1 showed encouraging preliminary evidence ofantitumor activity in subjects with HCC. This was especially true forthe subset of HCC subjects considered HBV positive. Compound 1 was welltolerated in these subjects, with a side effect profile comparable withother drugs targeting the mTOR pathway. Based on safety, PD, andefficacy data in this study, a starting dose of 30 mg daily is proposed.

6.2 Clinical Study 2

An Open-Label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor Compound 1 inHBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who have Receivedat Least One Prior Line of Systemic Therapy.

Indication.

Hepatitis B virus (HBV) positive, unresectable HCC subjects who havereceived at least one prior line of systemic therapy.

Objectives.

The primary objectives of the trial are: To evaluate pharmacokinetics(PK), safety, tolerability and overall response rate (ORR) of Compound 1in HBV+HCC subjects who have received at least one prior line ofsystemic therapy.

The secondary objectives of the trial are: To evaluate overall survival(OS), time to progression (TTP), progression-free survival (PFS),disease control rate (DCR), duration of response (DOR), time to response(TTR), and survival rate.

Trial Design.

This trial is an Asian multi-regional clinical trial (MRCT) in whichCompound 1 will be administered orally to hepatitis B positive (HBV+)HCC subjects who have received at least one prior line of systemictherapy. It is designed as an open-label phase 2 trial evaluating thepharmacokinetics (PK), safety, tolerability and efficacy of oralCompound 1 administered daily until the radiologic disease progression(according to RECIST 1.1) or intolerable toxicity.

Study Population.

Number and Population of Subjects: Approximately 30 HBV+, unresectableHCC subjects who have received at least one prior line of systemictherapy will be enrolled in this trial, including 6 at the dose of 15 mgand 24 at the dose of 30 mg. If the ORR in subjects with starting doseof 30 mg is greater than 15%, then this study may be expanded to enrolladditional approximately 96 subjects (approximately 120 subjectsreceiving the 30 mg starting dose level in total) using ORR as theprimary endpoint, to further evaluate the efficacy and safety.

Inclusion Criteria:

Male or female, ≥18 years of age at the time the ICF is signed;Confirmed pathologic or radiologic diagnosis of HCC according to theAmerican Association for the Study of Liver Disease (AASLD) guidelines;Unresectable stage B (intermediate) or C (advanced) HCC according to theBarcelona Clinic Liver Cancer (BCLC) staging. If stage B, the subjectmust have progressed after, or not be eligible for, surgical orlocoregional therapy; HBV+ is defined as chronic HBV infection or ahistory of HBV infection, based on any of the following serologicresults: HBcAb+, HBsAg+, HBV-DNA+; Received at least one prior line ofsystemic therapy (with radiologic disease progression during orfollowing sorafenib and/or chemotherapy). Subjects with alternativetreatments such as regorafenib and/or anti PD-1 antibodies etc. approvedby local health authorities are allowed to enter study if they meet allother inclusion/exclusion criteria; Chemotherapy includes FOLFOX(fluorouracil, leucovorin and oxaliplatin) or any otherplatinum-containing regimen; Chemotherapy≥two cycles; ECOG performancestatus score of 0 or 1; Satisfactory serum chemistry results, evidencedby the following: AST (SGOT) and ALT (SGPT)≤5× upper limit of normal(ULN); Total bilirubin≤2×ULN; Creatinine≤1.5×ULN or 24-hour clearance≥50mL/min; Adequate bone marrow function, evidenced by the following:Absolute neutrophil count (ANC)≥1.5×10⁹ cells/L, Platelets≥75×10⁹cells/L, Hemoglobin≥9 g/dL, Child-Pugh A (score 5 or 6 only) withoutencephalopathy; Male subjects (including those who have had a vasectomy)must agree to use a condom during sexual intercourse with females ofchild-bearing potential, and shall not conceive a child starting fromthe time of ICF signature, while on study medication, and for 3 monthsafter the last dose of study drug; Female subjects of child-bearingpotential must have both of the following: Agree to the use of two studyphysician-approved contraceptive methods simultaneously, or practicecomplete abstinence starting at the time of ICF signature, while onstudy medication, and for 28 days following the last dose of study drug.True abstinence: When this is in line with the preferred and usuallifestyle of the subject. Periodic abstinence (e.g., calendar,ovulation, symptothermal, post-ovulation methods) and withdrawal are notacceptable methods of contraception. Acceptable contraceptive methodsinclude: Oral, injectable, or implantable hormonal contraceptive;intra-uterine device; barrier contraceptive with spermicide; orvasectomized partner, together with at least one barrier method. Havenegative serum pregnancy test result at screening, confirmed by negativeurine pregnancy test within 72 hours prior to first dose of study drug(if serum test occurred >72 hours from first dose); pregnancy test musthave a sensitivity of at least 25 mIU/mL.

Exclusion Criteria:

The presence of any of the following will exclude a subject fromenrollment: Intolerant to sorafenib/regorafenib, e.g., the subject musthave discontinued either drug due to toxicity; Symptomatic centralnervous system metastases. Brain metastases that have previously beentreated and are stable for 4 weeks before the first dose date areallowed; Received sorafenib/regorafenib within 14 days prior toScreening; Locoregional HCC therapy (e.g., TACE, RFA), systemicchemotherapy, hormonal therapy (e.g., tamoxifen) or investigationaltherapy within 4 weeks (or 5 half-lives, whichever is shorter) prior toScreening; Tested positive for both HBV and hepatitis C virus (HCV).(HCV positive is defined as anti-HCV or HCV-RNA positive); Lifeexpectancy of less than 3 months; Prior therapy with mTOR (TORC1 and/orTORC2) inhibitors including sirolimus, temsirolimus, everolimus, andother investigational or approved mTOR/PI3K/AKT inhibitors; Majorsurgery or significant trauma within 28 days prior to Screening; Notrecovered from the acute toxic effects of prior anticancer therapy,radiation or major surgery/significant trauma at Screening; Minorsurgery within 7 days prior to Screening (excluding the placement ofcentral/peripheral lines or skin biopsy); Receiving active, ongoingtreatment with systemic corticosteroids at a prednisone equivalent doseof ≥10 mg daily or other systemic immune system modulators; Uncontrolleddiabetes, defined as HbAlc>8%; Prior organ transplant; Persistentdiarrhea or malabsorption≥National Cancer Institute (NCI) CommonTerminology Criteria for Adverse Events (CTCAE, Version 4.03) grade 2,despite medical management, or any significant gastrointestinal disorderthat could affect the absorption of study drug; Clinically significantbleeding, especially from esophageal varices, requiring medicalintervention within 28 days prior to Screening; Known history or currentdiagnosis of human immunodeficiency virus (HIV) infection, regardless oftreatment status; Concurrent active second malignancy for which thesubject is receiving therapy, excluding non-melanomatous skin cancer,non-progressive prostate cancer treated with hormonal therapy, orcarcinoma in situ of the cervix. Any cancer curatively treated >5 yearsprior to entry is permitted; Uncontrolled intercurrent illnessincluding, but not limited to ongoing or active infection (e.g.,tuberculosis) requiring antibiotic, antifungal, or antiviral therapy(other than anti-HBV therapy), symptomatic heart failure, cardiacarrhythmia, acute or chronic pancreatitis or psychiatric illness/socialsituations that would limit compliance with study requirements;Significant medical conditions, laboratory abnormalities, or psychiatricillnesses that would prevent the subject from complying fully with thisprotocol; Any condition including the presence of laboratoryabnormalities, which places subjects at unacceptable risk should theyparticipate in the trial; Any condition that confounds the ability tointerpret data from the trial.

Length of Trial.

Enrollment of the estimated 30 subjects is expected to takeapproximately 4 months. Completing PK, safety and preliminary efficacyevaluations is expected to take approximately 4 months. The end of Studyis defined as either the date of the last visit of the last subject tocomplete the trial, or the date of receipt of the last data point (e.g.,date of death) from the last subject that is required for primaryanalysis, whichever is the earlier date.

Study Treatments.

The starting dose of Compound 1 will be 15 mg daily for 28 days eachcycle for the first 6 fully evaluable (including PK outcomes) subjects.Providing dose-limiting toxicity (DLT) occurs in less than 2 of 6subjects who complete Cycle 1, additional 24 subjects will be enrolledat the starting dose of 30 mg daily. Subjects who tolerated the 15 mgdose level may then dose-escalate to 30 mg at the Investigator'sdiscretion until enrollment of 30 mg group starts. If the ORR insubjects with starting dose of 30 mg is greater than 15%, then thisstudy may be expanded to enroll additional approximately 96 subjects(approximately 120 subjects in total) using ORR as the primary endpoint, to further evaluate the efficacy and safety.

All subjects will receive Compound 1 once daily in continuous 28-daycycles (except cycle 1) until the appearance of radiologic diseaseprogression, toxicity, subject or physician decision or death. At thediscretion of the Investigator, treatment may continue beyond radiologicprogression until clear symptomatic deterioration if no other treatmentoptions are available. Dose interruptions of up to 3 weeks, and up totwo dose reductions (to 20 mg and 15 mg) will be allowed to mitigatetoxicity. Dose reescalation will be allowed only one time if the sametoxicity does not recur at the reduced dose for least one cycle (4weeks).

Antiviral therapy is required, and HBV-DNA viral load will be monitoredin all subjects with chronic HBV infection. Serum AST/ALT is alsomonitored.

After cessation of study drug treatment, subsequent anti-cancer therapyand survival status will be followed in all subjects until death.

Overview of Efficacy Assessments.

Subjects will be evaluated for tumor response and progression accordingto RECIST 1.1 guidelines every 8 weeks (±5 days) until radiologicdisease progression, death or withdrawal of consent. mRECIST may be alsoused when the trial is expanded, if necessary.

All anticancer treatments administered, especially for HCC, followingthe last dose of study drugs will be captured until death or withdrawalof consent. Disease progression and date of progression on eachsubsequent therapy will be documented. Following disease progression,survival will be followed every 8 weeks (±1 week) until death orwithdrawal of consent.

Overview of Safety Assessments.

All subjects will be monitored for adverse events, starting from thetime the subject signs the informed consent form (ICF) until 28 daysafter the last dose of study drug. A thorough evaluation of medicalconditions will be conducted during screening for eligibility. Vitalsigns, laboratory assessments (e.g. serum chemistry, hematology, fastingplasma glucose, glycated hemoglobin [HbAlc]), 12-lead electrocardiogram(ECGs), and ECOG performance status will be monitored. Contraceptionmust be practised during the trial to avoid pregnancy in trial subjectsand their partners, and females of child-bearing potential will haveregular pregnancy testing.

Overview of Pharmacokinetic Assessments.

Blood samples will be collected for intensive sampling in all 30subjects in order to estimate the PK of Compound 1 and metabolites inAsian subjects.

Overview of Exposure-Response Analyses.

Exposure-response analyses will be performed to evaluate relationshipsbetween Compound 1 and/or M1 exposure and clinical outcomes of efficacyand safety.

Overview of Biomarker Assessments.

Biomarkers will be evaluated. Inhibition of pAKT, pS6RP, p4EB-P1, and/orother relevant biomarkers will be assayed in peripheral blood and tumor.Correlative analyses will be completed for drug exposure, adverse eventsand clinical outcomes as appropriate.

6.3 Clinical Study 3

A Phase 2 Open-Label Trial of Dual TORC1/TORC2 Inhibitor Compound 1Combined with Nivolumab in HBV+ Advanced Hepatocellular Carcinoma (HCC)Subjects Previously Treated with Sorafenib

Indication.

Hepatitis B virus (HBV) positive, unresectable HCC subjects previouslytreated with sorafenib.

Objectives.

The primary objectives of the trial are: To evaluate safety,tolerability and overall response rate (ORR) of Compound 1 combined withnivolumab in HBV+HCC subjects previously treated with sorafenib.

The secondary objectives of the trial are: To evaluate duration ofresponse (DOR), survival rate, disease control rate (DCR), time toresponse (TTR), time to progression (TTP), progression-free survival(PFS), and overall survival (OS).

Trial Design.

This trial is an Asian multi-regional clinical trial (MRCT) in whichCompound 1 in low dose and following high dose will be administeredorally in combination with standard dose nivolumab in HBV+ advanced HCCsubjects previously treated with sorafenib. This is an open-label phase2 trial to evaluate the tolerability, safety and efficacy of Compound 1in combination with nivolumab.

Study Population.

Number and Population of Subjects: Approximately 30-42 HBV+,unresectable HCC subjects previously treated with sorafenib will beenrolled first. If the observed ORR of the combination therapy reachesapproximately 20%, then this trial may be expanded to approximately 126subjects in total using ORR as the primary end point, to furtherevaluate the efficacy and safety.

Inclusion Criteria:

Male or female, ≥18 years of age at the time the ICF is signed;Confirmed pathologic or radiologic diagnosis of HCC according to theAmerican Association for the Study of Liver Disease (AASLD) guidelines;Unresectable stage B (intermediate) or C (advanced) HCC according to theBarcelona Clinic Liver Cancer (BCLC) staging. If stage B, the subjectmust have progressed after, or not be eligible for, surgical orlocoregional therapy; Measurable disease as defined by RECIST 1.1;Radiologic disease progression following sorafenib treatment. Subjectswith alternative treatments such as regorafenib approved by local healthauthorities are allowed to enter study if they meet all otherinclusion/exclusion criteria; HBV+ is defined as chronic HBV infectionor a history of HBV infection, based on any of the following serologicresults: HBcAb+, HBsAg+, HBV-DNA+; Patients with active HBV infectionare required to be receiving effective antiviral therapy and their viralload should be <500 IU/mL before first study dose; ECOG performancestatus score of 0 or 1; Satisfactory serum chemistry results, evidencedby the following: AST (SGOT) and ALT (SGPT)≤5× upper limit of normal(ULN), Total bilirubin ≤2×ULN, Creatinine ≤1.5×ULN or 24-hourclearance≥50 mL/min; Adequate bone marrow function, evidenced by thefollowing: Absolute neutrophil count (ANC)≥1.5×10⁹ cells/L,Platelets≥75×10⁹ cells/L, Hemoglobin ≥9 g/dL, Child-Pugh A (score 5 or 6only) with no encephalopathy; Male subjects (including those who havehad a vasectomy) must agree to use a condom during sexual intercoursewith females of child-bearing potential, and shall not conceive a childstarting from the time of ICF signature, while on study medication, andfor 5 months after the last dose of study drug; Female subjects ofchild-bearing potential must have both of the following: Agree to theuse of two study physician-approved contraceptive methodssimultaneously, or practice complete abstinence starting at the time ofICF signature, while on study medication, and for 5 months following thelast dose of study drug. True abstinence: When this is in line with thepreferred and usual lifestyle of the subject. Periodic abstinence (e.g.,calendar, ovulation, symptothermal, post-ovulation methods) andwithdrawal are not acceptable methods of contraception. Acceptablecontraceptive methods include: Oral, injectable, or implantable hormonalcontraceptive; intra-uterine device; barrier contraceptive withspermicide; or vasectomized partner, together with at least one barriermethod. Have negative serum pregnancy test result at screening,confirmed by negative urine pregnancy test within 72 hours prior tofirst dose of study drug (if serum test occurred >72 hours from firstdose); pregnancy test must have a sensitivity of at least 25 mIU/mL.

Exclusion Criteria:

The presence of any of the following will exclude a subject fromenrollment: Intolerant to sorafenib, i.e., the subject must havediscontinued drug due to toxicity; Symptomatic central nervous systemmetastases. Metastases previously treated and stable for ≥4 weeks beforethe first dose date are allowed; History of hepatic encephalopathy;Received sorafenib within 14 days prior to first dose of study drug;Locoregional HCC therapy (e.g., TACE, RFA), systemic chemotherapy,hormonal therapy (e.g., tamoxifen) or investigational therapy within 4weeks (or 5 half-lives, whichever is shorter) prior to first dose ofstudy drug; Plan to receive locoregional HCC therapy (e.g., TACE, RFA)during the trial; Co-infection with HBV and HCV/HDV hepatitis virusinfection; Life expectancy of less than 3 months; Prior therapy withmTOR (TORC1 and/or TORC2) inhibitors including sirolimus, temsirolimus,everolimus, and other investigational or approved mTOR/PI3K/AKTinhibitors; Prior therapy with any medication targeting T-cellactivation or checkpoint pathways (including those targeting PD-1, PD-L1or PD-L2, CD137, or cytotoxic T-lymphocyte antigen [CTLA-4]); History ofautoimmune disease; Prior or current clinically significant ascites;Major surgery or significant trauma within 28 days prior to Screening;Not recovered from the acute toxic effects of prior anticancer therapy,radiation or major surgery/significant trauma at Screening; Minorsurgery within 7 days prior to Screening (excluding the placement ofcentral/peripheral lines or skin biopsy); Receiving active, ongoingtreatment with systemic corticosteroids at a prednisone equivalent doseof ≥10 mg daily or other systemic immune system modulators; Uncontrolleddiabetes, defined as HbAlc>8%; Prior organ transplant; Persistentdiarrhea or malabsorption≥National Cancer Institute (NCI) CommonTerminology Criteria for Adverse Events (CTCAE, Version 4.03) grade 2,despite medical management, or any significant gastrointestinal disorderthat could affect the absorption of study drug; Clinically significantbleeding, especially from esophageal varices, requiring medicalintervention within 28 days prior to Screening; Known history or currentdiagnosis of human immunodeficiency virus (HIV) infection, regardless oftreatment status; Concurrent active second malignancy for which thesubject is receiving therapy, excluding non-melanomatous skin cancer,non-progressive prostate cancer treated with hormonal therapy, orcarcinoma in situ of the cervix. Any cancer curatively treated >5 yearsprior to entry is permitted; Uncontrolled intercurrent illnessincluding, but not limited to ongoing or active infection (e.g.,tuberculosis) requiring antibiotic, antifungal, or antiviral therapy(other than anti-HBV therapy), symptomatic heart failure, cardiacarrhythmia, acute or chronic pancreatitis or psychiatric illness/socialsituations that would limit compliance with study requirements;Significant medical conditions, laboratory abnormalities, or psychiatricillnesses that would prevent the subject from complying fully with thisprotocol; Any condition including the presence of laboratoryabnormalities, which places subjects at unacceptable risk should theyparticipate in the trial; Any condition that confounds the ability tointerpret data from the trial.

Length of Trial.

Enrollment of the estimated 30-42 subjects is expected to takeapproximately 5 months. Completing tolerability, safety and preliminaryefficacy evaluations is expected to take approximately 8 months. The endof study is defined as either the date of the last visit of the lastsubject to complete the trial, or the date of receipt of the last datapoint (e.g., date of death) from the last subject that is required forprimary analysis, whichever is the earlier date.

Study Treatments.

Compound 1 will be administrated at different daily dose level (15 mg,30 mg or 20 mg) orally at the following schedule in combination withnivolumab given in a standard schedule (240 mg every 2 weeks,intravenous infusion). The dose escalation scheme will be based on amodified 3+3 design.

Initially 3 subjects will be enrolled in the cohort of Compound 1 15 mgcombination therapy: If no dose-limiting toxicity (DLT) occurs, 3 newsubjects will be enrolled in the cohort of Compound 1 30 mg combinationtherapy. If 1 DLT occurs, additional 3 subjects will be enrolled in theCompound 1 15 mg combination cohort. Providing no further DLTs occur, 3new subjects will be evaluated in the cohort of Compound 1 30 mgcombination. If 2 or more DLTs occur, it will be discussed with SafetyReview Committee and Principle Investigator(s) to discontinue trial orexplore other appropriate trial design.

For the initial 3 subjects in the cohort of Compound 1 30 mgcombination: If no DLT occurs, 24 new subjects will be enrolled at thedose level of Compound 1 30 mg combination. If 1 DLT occurs, additional3 subjects will be enrolled in the Compound 1 30 mg combination cohort.Providing no more than 1 DLT occurs in 6 subjects in the cohort ofCompound 1 30 mg combination, additional 24 subjects will be enrolled inthe cohort of Compound 1 30 mg combination. If 2 of 3 or 6 subjects atthe dose level of Compound 1 30 mg combination therapy experience DLTs,3 new subjects will be enrolled in a cohort of Compound 1 20 mgcombination. If no DLT occurs in the 3 subjects at the dose level ofCompound 1 20 mg combination, the study will proceed to enrolladditional 24 subjects at the dose level of Compound 1 20 mg combinationtherapy. If 1 DLT occurs, additional 3 subjects will be enrolled at thesame dose level of Compound 1 20 mg combination. Providing DLTs occur inless than 2 of 6 subjects in the cohort of Compound 1 20 mg combination,the study will proceed to enroll additional 24 subjects in the cohort ofCompound 1 20 mg combination. If 2 of 3 or 6 subjects at the dose levelof Compound 1 20 mg combination therapy experienced DLTs, the study willproceed to enroll additional 24 subjects in the cohort of Compound 1 15mg combination.

If the ORR of the combination therapy at optimal dose level reachesabout 20%, then this study will be expanded to a total of about 126subjects using ORR as the primary endpoint, in order to further evaluatethe efficacy and safety.

DLTs include early hyperglycemia, rash, fatigue, and mucositis, any ofwhich ≥grade 3, and hepatic impairment according to study CheckMate 040results, which commences within 6 weeks of first dose.

All subjects will receive Compound 1 orally once daily in continuous28-day cycles in combination with nivolumab intravenous infusion every 2weeks until the appearance of radiologic disease progression (accordingto RECIST 1.1), unacceptable toxicity, subject or physician decision,withdrawal of consent, or death. At the discretion of the Investigator,treatment may continue beyond radiologic progression until clearsymptomatic deterioration if no other treatment options are available.

Antiviral therapy is required, and HBV-DNA viral load will be monitoredin all subjects with chronic HBV infection. Serum AST/ALT is alsomonitored.

After cessation of study drug treatment, subsequent anti-cancer therapyand survival status will be followed in all subjects until death.

Overview of Efficacy Assessments.

Subjects will be evaluated for tumor response and progression accordingto RECIST 1.1 guidelines until radiologic disease progression, death orwithdrawal of consent. mRECIST may be also used when the trial isexpanded, if necessary. The tumor response assessments will be performedevery 6 weeks (±5 days) for first 24 weeks, and every 12 weeks (±1 week)thereafter.

All anticancer treatments administered, especially for HCC, followingthe last dose of combination treatment will be captured until death orwithdrawal of consent. Disease progression and date of progression oneach subsequent therapy will be documented. Following diseaseprogression, survival will be followed every 12 weeks (±1 week) untildeath or withdrawal of consent.

Overview of Safety Assessments.

All subjects will be monitored for adverse events, starting from thetime the subject signs the informed consent form (ICF) until 28 daysafter the last dose of combination treatment. A thorough evaluation ofmedical conditions will be conducted during screening for eligibility.Vital signs, laboratory assessments (e.g. serum chemistry, hematology,fasting plasma glucose, glycated hemoglobin [HbAlc]), 12-leadelectrocardiogram (ECGs), and ECOG performance status will be monitored.Contraception must be practiced during the trial to avoid pregnancy intrial subjects and their partners, and females of child-bearingpotential will have regular pregnancy testing.

Overview of Biomarker Assessments.

Biomarkers will be evaluated. Inhibition of pAKT, pS6RP, p4EB-P1, and/orother relevant biomarkers will be assayed in peripheral blood and tumortissue. Correlative analyses will be completed for drug exposure,adverse events and clinical outcomes as appropriate.

From the foregoing, it will be appreciated that, although specificembodiments have been described herein for the purpose of illustration,various modifications may be made without deviating from the spirit andscope of what is provided herein. All of the references referred toabove are incorporated herein by reference in their entireties.

1-45. (canceled)
 46. A method for treating hepatocellular carcinoma(HCC) characterized by hepatitis B virus (HBV) infection in a patient,comprising administering an effective amount of7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-oneor a pharmaceutically acceptable salt or tautomer thereof to the patienthaving HCC characterized by HBV infection; wherein7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-oneor a pharmaceutically acceptable salt or tautomer thereof isadministered in combination with a second therapeutic agent; and whereinthe second therapeutic agent is an anti-CTLA-4 antibody.
 47. The methodof claim 46, wherein the anti-CTLA-4 antibody is ipilimumab.
 48. Themethod of claim 46, wherein HBV infection is determined by at least oneof the variables selected from the group consisting of: patient historyof HBV, prior or current treatment for HBV, cirrhosis attributed to HBV,the presence of HBV proteins or antigens, the presence of antibodies toHBV proteins or antigens, HBV viral load, and the presence of HBV DNA.49. The method of claim 46, wherein HBV infection is determined bypatient history of HBV.
 50. The method of claim 46, wherein HBVinfection is determined by prior treatment for HBV.
 51. The method ofclaim 46, wherein HBV infection is determined by current treatment forHBV.
 52. The method of claim 46, wherein HBV infection is determined bycirrhosis attributed to HBV.
 53. The method of claim 46, wherein HBVinfection is determined by the presence of HBV proteins or antigens. 54.The method of claim 46, wherein HBV infection is determined by thepresence of antibodies to HBV proteins or antigens.
 55. The method ofclaim 46, wherein HBV infection is determined by HBV viral load.
 56. Themethod of claim 46, wherein HBV infection is determined by the presenceof HBV DNA.
 57. The method of claim 46, wherein HBV infection isdetermined by at least one of the variables selected from the groupconsisting of the presence of HBV surface antigen (HBsAG), the presenceof HBV core antigen (HBcAG), the presence of HBV envelope antigen(HBeAg), the presence of HBV x antigen (HBxAg), the presence of HBVcore-related antigen (HBcrAg), the presence of antibody to HBV surfaceantigen (anti-HBsAg), the presence of antibody to HBV core antigen(anti-HBcAg), the presence of antibody to HBV envelope antigen(anti-HBeAg), the presence of antibody to HBV x antigen (anti-HBxAg),the presence of antibody to HBV core-related antigen (anti-HBcrAg), theuse of HBV medications, HBV viral load, the presence of HBV DNA, thepresence of HBV mRNA, and the presence of HBV protein.
 58. The method ofclaim 46, wherein the HCC is unresectable HCC.
 59. The method of claim46, wherein the HCC is previously untreated HCC.
 60. The method of claim46, wherein the HCC is previously treated HCC, wherein the previoustreatment comprises sorafenib.
 61. The method of claim 46, wherein theHCC is previously treated HCC, wherein the previous treatment compriseschemotherapy.